DRUG NAME: Cefotetan

INN: Cefotetan
Salt form in formulations: Cefotetan disodium (parenteral)

ℹ️ All doses in this monograph are expressed as cefotetan base equivalent unless otherwise stated.

⚠️ AVAILABILITY WARNING — CRITICAL FOR INDIAN PRESCRIBERS

Cefotetan is NOT currently marketed in India. No CDSCO-approved formulation is identified, and no Indian pharmaceutical manufacturer is known to produce cefotetan as of the date of this monograph. The drug has been primarily available in the United States (originally marketed as Cefotan® by AstraZeneca/Zeneca — supply has been intermittent and limited in recent years globally).

The closely related cephamycin AVAILABLE in India is cefoxitin (multiple Indian manufacturers — brands include Cefomycin, Mefoxin generics, and several generic cefoxitin sodium injection products).

Purpose of this monograph: This entry is provided as a clinical pharmacology reference for Indian prescribers who may encounter cefotetan in:

International clinical guidelines (particularly US-origin surgical prophylaxis and PID treatment guidelines that recommend cefotetan by name)
Clinical trials and international literature
Imported drug supplies for specific patients or institutions
Comparative pharmacology discussions with cefoxitin (the Indian alternative)

For practical clinical use in India: cefoxitin is the available cephamycin. Key differences between cefotetan and cefoxitin are highlighted throughout this monograph to aid clinicians translating international guidelines into Indian practice.

Chemical Classification Note

ℹ️ Cefotetan is a cephamycin — NOT a true cephalosporin, though it is conventionally classified alongside second-generation cephalosporins. Cephamycins are produced by Streptomyces species (not Cephalosporium/Acremonium like true cephalosporins) and possess a unique 7α-methoxy group on the cephem ring. This methoxy group:

Confers resistance to hydrolysis by many beta-lactamases (including some chromosomal AmpC beta-lactamases that inactivate true cephalosporins)
Provides clinically significant anaerobic activity — particularly against Bacteroides fragilis group — which true second-generation cephalosporins (cefuroxime, cefaclor, cefprozil) lack

The two cephamycins of clinical relevance are:

Cefotetan — NOT available in India (this monograph)
Cefoxitin — AVAILABLE in India (the practical alternative)

ℹ️ Cefotetan also possesses the N-methylthiotetrazole (NMTT) side chain at the 3-position of the cephem ring. This side chain is responsible for two clinically critical adverse effects unique to NMTT-containing beta-lactams:

⚠️ Disulfiram-like reaction with alcohol
⚠️ Hypoprothrombinemia / coagulopathy (vitamin K antagonism)

Cefoxitin does NOT have the NMTT side chain and therefore does NOT cause these two adverse effects — a key safety advantage of cefoxitin over cefotetan.

Therapeutic Class:

Antibiotic

Subclass:

Cephamycin (classified with Second-Generation Cephalosporins)

ℹ️ Cephamycins are pharmacologically distinct from true second-generation cephalosporins (cefuroxime, cefaclor, cefprozil) in two key ways: (1) anaerobic coverage (particularly B. fragilis) and (2) enhanced beta-lactamase stability (7α-methoxy group). However, they share the same general spectrum positioning between first-generation (excellent gram-positive, limited gram-negative) and third-generation (broad gram-negative, reduced gram-positive) cephalosporins.

Schedule (India):

Not currently marketed in India — no Indian schedule classification exists.

ℹ️ If cefotetan were to be marketed in India, it would likely be classified under Schedule H of the Drugs and Cosmetics Act (consistent with other parenteral cephalosporin/cephamycin antibiotics). The related cephamycin cefoxitin is classified as Schedule H in India.

Route(s)

IV (slow IV injection / bolus over 3–5 minutes, or intermittent IV infusion over 20–60 minutes)
IM (deep intramuscular injection)

ℹ️ Cefotetan is a parenteral-only drug. No oral formulation exists anywhere globally. Unlike cefuroxime (which has both IV cefuroxime sodium and oral cefuroxime axetil), cefotetan cannot be used for outpatient oral therapy or oral step-down. If oral step-down from cefotetan is required, the prescriber must switch to a different oral antibiotic with appropriate spectrum coverage (e.g., amoxicillin-clavulanate for mixed aerobic-anaerobic infections).

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. Cefotetan is a small-molecule chemical drug (semi-synthetic cephamycin antibiotic).

Formulations Available in India

⛔ NOT CURRENTLY MARKETED IN INDIA

No cefotetan formulation (any strength, any manufacturer) is identified as CDSCO-approved or commercially available in Indian pharmacies, hospitals, or government supply chains as of the date of this monograph.

Formulations Available Globally (For Reference)

Dosage Form	Strengths Available	Salt Form	Notes
Powder for injection (vial)	1 g, 2 g	Cefotetan disodium	Reconstitution required. Previously marketed as Cefotan® (AstraZeneca/Zeneca, US). Generic cefotetan for injection has been available from US generic manufacturers (e.g., Sandoz, Sagent). Global supply has been intermittent.
Premixed frozen solution (Galaxy® container)	1 g/50 mL, 2 g/50 mL	Cefotetan disodium in iso-osmotic dextrose	For IV infusion only. US hospital market. Thaw before use.

FDCs and Banned Formulations

No FDCs containing cefotetan exist
No cefotetan-containing formulation has been banned in India (as the drug has never been marketed here)

PHARMACOKINETICS

ℹ️ All PK parameters are for the parenteral route (IV/IM). No oral PK data exists because no oral formulation has been developed.

Primary PK Table

Parameter	Value
Bioavailability	IV: 100%. IM: well absorbed, essentially complete bioavailability (~98%).
Tmax	IV bolus: end of injection (immediate). IM: ~1.5–3 hours.
Protein binding	~76–91% (concentration-dependent; higher protein binding at lower drug concentrations). ℹ️ This is significantly higher than cefoxitin (~65–79%) and most other cephalosporins. The high protein binding means a lower free drug fraction (~9–24%) — pharmacodynamically relevant for a time-dependent antibiotic (only free drug is microbiologically active). Despite this, the very long half-life compensates by maintaining adequate free drug concentrations above MIC for extended periods.
Volume of distribution (Vd)	~0.14–0.17 L/kg — low. Distributes into: bile (moderate concentrations), peritoneal fluid, uterine tissue, fallopian tubes, ovarian tissue (basis for gynaecological infection treatment), skin/subcutaneous tissue (basis for surgical prophylaxis), and urinary tract (very high urinary concentrations). ⛔ Poor CSF penetration — NOT recommended for meningitis.
Metabolism	NOT metabolised. Cefotetan is excreted unchanged. No active or inactive metabolites. NOT a substrate, inhibitor, or inducer of CYP450 enzymes. However, the NMTT side chain has independent pharmacological effects (see NMTT section below). Drug transporter profile: Substrate of OAT1/OAT3 (organic anion transporters — mediates renal tubular secretion). Probenecid inhibits OAT-mediated secretion → increases cefotetan levels. Not a clinically significant substrate of P-glycoprotein, OATP1B1/1B3, BCRP, OCT2, or MATE1/2 at therapeutic concentrations.
Half-life (t½)	~3.0–4.6 hours — this is the LONGEST half-life among second-generation cephalosporins and cephamycins. ℹ️ Compare: cefoxitin ~0.7–1 hour, cefuroxime ~1–2 hours, cefazolin ~1.8–2.5 hours. The long half-life is the principal pharmacokinetic advantage of cefotetan — allowing q12h dosing (vs q6–8h for cefoxitin). Prolonged in renal impairment: CrCl 10–30 mL/min → t½ ~10 hours; CrCl <10 mL/min → t½ ~13–25 hours.
Excretion	Primarily renal: ~50–80% excreted unchanged in urine via glomerular filtration and active tubular secretion (OAT-mediated). Achieves very high urinary concentrations (>1000 mcg/mL). Approximately ~20% excreted via biliary route (minor).
Dialysability	Minimally removed by haemodialysis (~6–10% removed during a standard 4-hour HD session) — due to high protein binding. Supplemental dosing post-HD is generally NOT required but some sources recommend a supplemental dose for patients receiving full therapeutic dosing on HD days. Not significantly removed by peritoneal dialysis.
Food effect	Not applicable — parenteral-only drug.
Onset of action	IV: immediate — therapeutic serum levels at end of injection. IM: serum levels peak at ~1.5–3 hours; effective tissue levels for surgical prophylaxis achieved within 30–60 minutes of IM injection. Clinical improvement in infections: typically within 48–72 hours.
Duration of action	The long half-life (~3–4.6 hours) allows sustained serum levels above MIC for susceptible organisms throughout a 12-hour dosing interval. This supports q12h dosing — a significant practical advantage for nursing administration in hospital settings. For surgical prophylaxis: a single pre-operative dose provides adequate tissue levels for procedures lasting up to 4–6 hours without intraoperative re-dosing (re-dose if procedure exceeds 6 hours or blood loss >1500 mL).

NMTT Side Chain — Clinically Critical Pharmacological Feature

⚠️ This is the most important pharmacological distinction between cefotetan and cefoxitin.

Cefotetan contains the N-methylthiotetrazole (NMTT/MTT) side chain at the 3-position of the cephem ring. This structural feature is shared with a small group of beta-lactams: cefotetan, cefamandole, cefoperazone (available in India), and moxalactam (latamoxef). The NMTT side chain is released in vivo during drug elimination and causes two distinct pharmacological effects:

⚠️ Effect 1: Disulfiram-Like Reaction with Alcohol

Parameter	Details
Mechanism	NMTT inhibits aldehyde dehydrogenase (the enzyme that metabolises acetaldehyde to acetic acid). When alcohol is consumed, acetaldehyde accumulates → toxic effects.
Clinical manifestation	Flushing, nausea, vomiting, headache, tachycardia, hypotension, diaphoresis, abdominal cramps. Severity ranges from mild discomfort to cardiovascular collapse in rare cases.
Timing	Reaction can occur if alcohol is consumed during therapy and for up to 72 hours after the last dose of cefotetan.
Clinical action	⛔ Absolute alcohol avoidance — counsel patients/nursing staff. Includes: ethanol beverages, alcohol-containing medications (many Indian cough syrups, tonics), alcohol-based topical products applied to large surface areas, alcohol-containing IV medications/diluents.
Duration of risk	Continue alcohol avoidance for at least 72 hours (3 full days) after the last dose.

💡 Cefoxitin does NOT cause disulfiram-like reactions — it lacks the NMTT side chain. This is a key safety advantage of cefoxitin over cefotetan in Indian practice where alcohol-containing traditional remedies and cough syrups are commonly used.

💡 Cefoperazone (available in India as cefoperazone-sulbactam FDC) ALSO has the NMTT side chain and carries the same disulfiram-reaction risk. Indian prescribers who are aware of the cefoperazone-alcohol interaction will recognise the same mechanism in cefotetan.

⚠️ Effect 2: Hypoprothrombinemia / Coagulopathy

Parameter	Details
Mechanism	NMTT interferes with hepatic vitamin K–dependent carboxylation of clotting factors II (prothrombin), VII, IX, and X. This is mechanistically analogous to warfarin’s action — though less potent and occurring primarily with prolonged courses or predisposing risk factors.
Clinical manifestation	Prolonged PT/INR → increased bleeding risk. Can manifest as: bruising, surgical site bleeding, haematuria, GI bleeding, epistaxis.
Risk factors for clinically significant coagulopathy	(1) Prolonged courses (>5–7 days); (2) Malnutrition or vitamin K deficiency (common in hospitalised Indian patients); (3) Pre-existing liver disease; (4) Concurrent anticoagulant therapy (warfarin, acenocoumarol, heparin); (5) Renal impairment (drug accumulation → NMTT accumulation); (6) Bowel sterilisation by the antibiotic (reduces gut bacterial vitamin K synthesis — additive to NMTT effect); (7) NPO (nil per oral) status.
Prevention	Prophylactic vitamin K supplementation is recommended for courses ≥5 days and in patients with any risk factor: Vitamin K₁ (phytomenadione) 10 mg IV or IM once weekly during cefotetan therapy. Some institutions give vitamin K₁ 10 mg at the start of cefotetan therapy.
Monitoring	Check PT/INR at baseline and at day 3–5 of therapy (or more frequently if risk factors present). If PT prolonged: administer vitamin K₁ 10 mg IV/IM and reassess. If clinically significant bleeding: stop cefotetan, give vitamin K₁, FFP if needed.

💡 Cefoxitin does NOT cause hypoprothrombinemia — it lacks the NMTT side chain. This is the second key safety advantage of cefoxitin over cefotetan, particularly relevant in:

Post-operative patients (bleeding risk at surgical site)
Malnourished patients (common in Indian hospital populations)
Patients on concurrent anticoagulants

PK-PD Target (Antimicrobial-Specific)

Parameter	Details
Primary efficacy index	%fT > MIC (percentage of the dosing interval during which the free [unbound] drug concentration exceeds the MIC of the pathogen) — standard for all beta-lactams.
Target value	fT > MIC ≥ 40–50% for bacteriostatic effect; ≥ 60–70% for maximal bactericidal killing.
Dosing justification	Despite the relatively high protein binding (~76–91%), the very long half-life (~3–4.6 hours) ensures that even the free drug fraction maintains concentrations above typical MIC values of susceptible organisms for the majority of a 12-hour dosing interval. This pharmacokinetic profile justifies the q12h dosing of cefotetan — a practical advantage over cefoxitin (t½ ~0.7–1 hr → requires q6–8h dosing to maintain adequate fT > MIC).
Clinical implication	The q12h dosing reduces nursing workload, IV access time, and total infusion episodes per day — particularly advantageous in resource-constrained Indian hospital settings where nursing ratios are often suboptimal. However, this advantage is theoretical for India since cefotetan is unavailable; cefoxitin (q6–8h) is the available cephamycin.

Post-Antibiotic Effect (PAE)

Organism Category	PAE	Clinical Relevance
Gram-positive cocci	Moderate (~1–2 hours)	Contributes modestly to dosing interval adequacy
Gram-negative bacilli	Minimal to absent (~0–0.5 hours)	Typical for beta-lactams against gram-negatives — %fT > MIC remains the primary efficacy driver
Anaerobes (B. fragilis)	Limited data; likely minimal	PAE does not significantly contribute to anaerobic efficacy; time-dependent killing predominates

ℹ️ The PAE of cefotetan is NOT clinically significant enough to allow extended-interval dosing beyond the standard q12h regimen. The long half-life (not PAE) is the primary justification for q12h dosing.

Spectrum of Activity

ℹ️ Placement note: Per the antimicrobial class-specific checklist, this spectrum table precedes the Indications section (Part 2). It is included in Part 1 as an integral component of the drug’s pharmacological profile.

Organism	Activity	Notes
S. aureus — MSSA	✅ Moderate	Active against methicillin-susceptible strains. Less potent than first-generation cephalosporins (cefazolin) or antistaphylococcal penicillins (cloxacillin). ⛔ NOT active against MRSA.
Coagulase-negative staphylococci (methicillin-susceptible)	✅ Moderate
Streptococcus pyogenes (GAS)	✅ Good
Streptococcus pneumoniae	✅ Moderate (penicillin-susceptible)	⚠️ NOT reliably active against penicillin-resistant pneumococcus.
Streptococcus agalactiae (GBS)	✅ Good
Enterococci	⛔ NOT active	Intrinsic resistance to all cephalosporins and cephamycins.
Escherichia coli (non-ESBL)	✅ Good	Better gram-negative activity than cefoxitin (lower MICs for most Enterobacterales). ⛔ NOT active against ESBL producers.
Klebsiella pneumoniae (non-ESBL)	✅ Good	Same ESBL caveat.
Proteus mirabilis	✅ Good
Proteus vulgaris	✅ Moderate-Good	Better activity than cefoxitin against indole-positive Proteus.
Haemophilus influenzae	✅ Good	Including beta-lactamase producers.
Moraxella catarrhalis	✅ Good	Including beta-lactamase producers.
Neisseria gonorrhoeae	✅ Good (historically)	⚠️ Gonococcal resistance is increasing globally. Do NOT use for gonorrhoea — current NACO/ICMR and WHO guidelines recommend ceftriaxone. However, cefotetan 2 g IM + probenecid is included in CDC PID treatment regimens as a single-dose gonococcal component (US-specific).
Neisseria meningitidis	✅ Moderate	But NOT recommended for meningitis (poor CSF penetration).
Serratia marcescens	⚠️ Variable	Some strains susceptible. Culture-guided only.
Providencia spp.	✅ Moderate
Morganella morganii	⚠️ Variable	May be intrinsically resistant via AmpC.
Citrobacter spp.	⚠️ Variable	May be resistant via inducible AmpC — do NOT use for Citrobacter without confirmed susceptibility.
Enterobacter spp.	⚠️ Unreliable — AVOID	Inducible AmpC beta-lactamase producers. Cephamycins can select for stably derepressed AmpC mutants → emergence of resistance on therapy. ⛔ Clinical failure risk even if initially susceptible in vitro.
ESBL-producing Enterobacterales	⛔ NOT reliably active	Although cephamycins (cefotetan, cefoxitin) are structurally resistant to ESBL enzymes in vitro, clinical efficacy against ESBL producers is unreliable due to porin loss, co-existing resistance mechanisms, and high inocula. ⛔ Do NOT use cefotetan for documented ESBL infections.
Pseudomonas aeruginosa	⛔ NOT active	No antipseudomonal activity.
Acinetobacter baumannii	⛔ NOT active
Stenotrophomonas maltophilia	⛔ NOT active
Listeria monocytogenes	⛔ NOT active	ALL cephalosporins and cephamycins are intrinsically inactive against Listeria.
Bacteroides fragilis group	✅ Moderate-Good (BUT increasing resistance)	⚠️ CRITICAL caveat: B. fragilis group resistance to cephamycins (both cefotetan and cefoxitin) has been increasing over the past two decades. Resistance rates of 15–30% (and higher in some centres) have been reported. Cefoxitin generally retains slightly better activity against B. fragilis than cefotetan (lower MIC90 values in most surveys). For life-threatening anaerobic infections, metronidazole or carbapenems are more reliable than cephamycins.
Prevotella spp.	✅ Good
Fusobacterium spp.	✅ Good
Peptostreptococcus spp.	✅ Good
Clostridium perfringens	✅ Good
Clostridioides difficile	⛔ NOT active — can CAUSE CDI	Like all cephalosporins, cefotetan disrupts colonic flora and predisposes to C. difficile infection.
Atypical organisms (Mycoplasma, Chlamydophila, Legionella)	⛔ NOT active
MRSA	⛔ NOT active	mecA-mediated resistance = resistant to ALL beta-lactams (except anti-MRSA cephalosporins: ceftaroline, ceftobiprole).

Comparative Pharmacokinetic & Pharmacological Table: Cefotetan vs Cefoxitin vs Cefuroxime

ℹ️ This comparison is the most clinically relevant content in this monograph for Indian prescribers, because cefoxitin is the Indian alternative when international guidelines recommend cefotetan.

Parameter	Cefotetan (NOT available in India)	Cefoxitin (AVAILABLE in India)	Cefuroxime (AVAILABLE in India)
Chemical class	Cephamycin	Cephamycin	True cephalosporin (2nd gen)
7α-methoxy group	✅ Yes → BL stability + anaerobic activity	✅ Yes → BL stability + anaerobic activity	❌ No
NMTT side chain	⚠️ YES → Disulfiram + coagulopathy	✅ NO → No disulfiram, no coagulopathy	✅ NO
Route	IV, IM	IV, IM	IV, IM, Oral (cefuroxime axetil)
Half-life	~3–4.6 hr (longest)	~0.7–1 hr (shortest)	~1–2 hr
Dosing frequency	q12h (BID)	q6–8h (TID-QID)	q8h (TID)
Protein binding	~76–91% (high)	~65–79% (moderate-high)	~33–50% (moderate)
Free drug fraction	~9–24%	~21–35%	~50–67%
Renal elimination (unchanged)	~50–80%	~85%	~85–95%
Renal dose adjustment	⚠️ Yes	⚠️ Yes	⚠️ Yes
Dialysability	Minimal (~6–10%) — high protein binding	Moderate (~20–30%)	Moderate (~50%)
Anaerobic coverage (B. fragilis)	✅ Yes (but 15–30% resistance)	✅ Yes — slightly BETTER than cefotetan	⛔ No
Gram-negative coverage (Enterobacterales)	✅ Better than cefoxitin (lower MICs)	✅ Good	✅ Good
MSSA coverage	✅ Moderate	✅ Moderate	✅ Good
Enterococcal coverage	⛔ None	⛔ None	⛔ None
Pseudomonas coverage	⛔ None	⛔ None	⛔ None
ESBL coverage	⛔ Unreliable	⛔ Unreliable	⛔ None
Alcohol interaction (disulfiram-like)	⚠️ YES — 72 hr avoidance	✅ No	✅ No
Coagulopathy risk (NMTT)	⚠️ YES — vitamin K prophylaxis recommended	✅ No	✅ No
NLEM India 2022	❌ Not listed (not marketed)	❌ Not listed	✅ Injection listed (750 mg, 1.5 g)
Availability in India	⛔ NOT available	✅ Available — multiple manufacturers	✅ Available — widely used
IV-to-oral step-down (same molecule)	⛔ Not possible (no oral form)	⛔ Not possible (no oral form)	✅ Yes (cefuroxime sodium → cefuroxime axetil)
Surgical prophylaxis re-dosing interval	q6h intra-op (re-dose at 6 hrs)	q2–3h intra-op (re-dose at 2–3 hrs — short t½)	q3–4h intra-op
Key clinical advantage	Long t½ → q12h dosing, better gram-negative MICs, single pre-op dose for long procedures	No NMTT side chain → no disulfiram, no coagulopathy. Better B. fragilis activity. Available in India.	Oral formulation available → IV-to-oral step-down. Good respiratory pathogen coverage. NLEM-listed.
Key clinical disadvantage	NMTT → disulfiram + coagulopathy. NOT available in India. High protein binding.	Short t½ → q6–8h dosing (nursing workload).	No anaerobic coverage.

Key Clinical PK Distinctions of Cefotetan

💡 1. The longest half-life among cephamycins/second-gen cephalosporins enables convenient q12h dosing — but this advantage is unavailable in India.
Cefotetan’s ~3–4.6 hour half-life is 3–6 times longer than cefoxitin’s ~0.7–1 hour, allowing twice-daily dosing vs three-to-four-times-daily dosing. For hospital settings with limited nursing staff (common in Indian district hospitals), this would reduce IV administration burden. However, since cefotetan is not available in India, this advantage remains theoretical. Indian prescribers must use cefoxitin’s q6–8h regimen when a cephamycin is needed.

💡 2. The NMTT side chain is clinically consequential — understand it, especially if prescribing cefoperazone (available in India).
Indian prescribers are more likely to encounter the NMTT side chain through cefoperazone (widely available in India as cefoperazone-sulbactam combinations) than through cefotetan. The pharmacology is identical: disulfiram-like reaction with alcohol and hypoprothrombinemia risk. Knowledge of cefotetan’s NMTT pharmacology directly translates to safer prescribing of cefoperazone-sulbactam in India.

💡 3. High protein binding (~76–91%) limits free drug availability but is compensated by the long half-life.
Despite the high protein binding (only ~9–24% free drug), the prolonged serum persistence ensures adequate time above MIC. However, in hypoalbuminaemic patients (common in critically ill Indian patients — malnutrition, sepsis, burns, liver disease), free drug fraction increases → higher peak free drug levels but also faster clearance → half-life may be shortened. Consider more frequent dosing (q8h instead of q12h) in severely hypoalbuminaemic patients, though formal data are limited.

💡 4. Minimal dialysability due to high protein binding — no post-HD supplementation usually needed.
Unlike cefuroxime (~50% removed by HD) or cefoxitin (~20–30% removed), cefotetan is minimally dialysed (~6–10%). This means doses given pre-dialysis are not significantly lost during the HD session. However, the NMTT side chain metabolite may also be poorly dialysed — potentially increasing coagulopathy risk in HD patients on prolonged courses. Monitor PT/INR carefully.

Population Pharmacokinetic Notes

Population	Clinical PK Significance
Renal impairment	⚠️ Clinically significant. Half-life prolonged: CrCl 10–30 mL/min → t½ ~10 hours; CrCl <10 mL/min → t½ ~13–25 hours. Dose reduction AND/OR interval extension required (see Renal Adjustment, Part 3). NMTT side chain effects (coagulopathy) may be amplified due to drug accumulation.
Hepatic impairment	Cefotetan is NOT hepatically metabolised. No dose adjustment for hepatic impairment per se. However, patients with liver disease may have: (1) reduced vitamin K stores → AMPLIFIED NMTT-induced coagulopathy; (2) hypoalbuminaemia → increased free drug fraction; (3) concurrent coagulopathy from liver disease itself → additive bleeding risk. Monitor PT/INR closely.
Obesity	Limited formal PK data. Given the low Vd (~0.14–0.17 L/kg based on total body weight), standard weight-based dosing may result in lower tissue concentrations in obese patients. For surgical prophylaxis in morbidly obese patients (BMI ≥40): consider using the 2 g dose (rather than 1 g) for adequate tissue penetration. Some US guidelines recommend 2 g for all surgical prophylaxis regardless of weight.
Pregnancy	Increased GFR → accelerated renal clearance → potentially lower serum levels. Standard doses remain adequate for most indications. Cefotetan crosses the placenta. No teratogenicity data of concern (cephalosporin/cephamycin class safety). Used in pregnancy for PID treatment (CDC guidelines recommend cefotetan-based regimens during pregnancy if needed).
Elderly (≥60 years)	Age-related GFR decline → prolonged half-life. Dose adjustment based on CrCl calculation (Cockcroft-Gault). Increased risk of NMTT-related coagulopathy (nutritional deficiency, polypharmacy with anticoagulants, hepatic dysfunction more common in elderly). Monitor PT/INR.
Paediatric	Limited PK data in children. Half-life in children >1 year: ~1.5–3 hours (shorter than adults, attributed to higher GFR per kg). Weight-based dosing used: 20–40 mg/kg/dose q12h (see Part 3). Neonatal PK data: very limited — prolonged half-life expected due to renal immaturity.
Critical illness / ICU	Increased Vd in sepsis/fluid overload → lower serum concentrations. Hypoalbuminaemia → increased free drug fraction but faster clearance. ARC (CrCl >130 mL/min) in young, non-elderly ICU patients → subtherapeutic levels possible with standard dosing. Consider q8h dosing in ARC. However, cefotetan is rarely the antibiotic of choice in critically ill ICU patients who typically need broader-spectrum agents.

Cefotetan vs Amoxicillin-Clavulanate — Comparator for Mixed Aerobic-Anaerobic Infections

ℹ️ Since cefotetan is unavailable in India, and cefoxitin (while available) competes with amoxicillin-clavulanate for many of the same indications, this comparison provides additional clinical context.

Feature	Cefotetan	Amoxicillin-Clavulanate
Route	IV, IM only	IV AND Oral → step-down advantage
Anaerobic coverage (B. fragilis)	✅ Yes (15–30% resistance)	✅ Yes (~10–20% resistance — slightly better)
Enterococcal coverage	⛔ None	✅ E. faecalis (amoxicillin component)
Gram-negative coverage	✅ Good (non-ESBL Enterobacterales)	✅ Good (but ESBL resistance applies equally)
MSSA coverage	✅ Moderate	✅ Good
NMTT side chain risks	⚠️ Yes (disulfiram + coagulopathy)	✅ No
GI tolerability	✅ Good (IV — no oral GI effects)	⚠️ Diarrhoea ~10–25% (clavulanate-driven)
Hepatotoxicity risk	✅ Negligible	⚠️ Cholestatic DILI (clavulanate-associated) — uncommon but documented
NLEM India 2022	❌ Not listed	✅ Listed
Cost (India)	N/A (not available)	✅ Affordable — NPPA-controlled
Availability in India	⛔ Not available	✅ Widely available

💡 Clinical decision summary for Indian practice: For most mixed aerobic-anaerobic infections where international guidelines recommend cefotetan (e.g., PID, intra-abdominal infections, surgical prophylaxis for colorectal/GYN procedures), Indian prescribers can use:

Cefoxitin (direct cephamycin substitute — same pharmacological class, available in India)
Amoxicillin-clavulanate (broader coverage including enterococci, available IV + oral, NLEM-listed)
Cephalosporin + metronidazole (e.g., cefuroxime IV/oral + metronidazole IV/oral — both NLEM-listed, provides aerobic + anaerobic coverage, IV-to-oral step-down possible)
Ampicillin-sulbactam (available in India — good anaerobic coverage, no NMTT risk)
Piperacillin-tazobactam (for more severe/healthcare-associated infections)

ADULT INDICATIONS + DOSING

⚠️ CRITICAL AVAILABILITY REMINDER

Cefotetan is NOT marketed in India. All indications and dosing below are provided as a pharmacological reference for Indian prescribers who encounter cefotetan recommendations in international guidelines. For each indication, the Indian alternative is explicitly stated. In clinical practice in India, prescribers should use the Indian alternative — NOT attempt to source cefotetan.

⚠️ ANTIMICROBIAL STEWARDSHIP NOTES FOR CEFOTETAN

1. Classification within antimicrobial stewardship frameworks:
Cefotetan is a second-line cephamycin — not a first-line agent for any infection. Its primary clinical niche is providing combined aerobic + anaerobic coverage in a single parenteral agent for:

Surgical prophylaxis (colorectal, gynaecological)
Mixed aerobic-anaerobic infections (intra-abdominal, pelvic)

In antimicrobial stewardship terms, cefotetan fills the same ecological niche as:

Cefoxitin (available in India — preferred cephamycin alternative)
Amoxicillin-clavulanate IV (available in India — NLEM-listed)
Ampicillin-sulbactam IV (available in India)
Cephalosporin + metronidazole combination (widely available in India)

2. When narrower-spectrum alternatives should be preferred:

For clean surgical prophylaxis (orthopaedic, cardiac, hernia) where anaerobic coverage is NOT needed: Use cefazolin (NLEM-listed, cheaper, better MSSA activity, no NMTT risk)
For pure gram-positive SSTIs: Use cefazolin or cloxacillin (NLEM-listed)
For community-acquired respiratory infections: Use cefuroxime or amoxicillin-clavulanate (NLEM-listed, oral step-down available)
For uncomplicated UTI: Use nitrofurantoin or fosfomycin (NLEM-listed, oral)

3. Resistance context for India (ICMR AMR data):
Although cefotetan itself is not tested in Indian antibiograms, the organisms it covers are subject to Indian resistance patterns:

⚠️ ESBL prevalence in Indian E. coli: 40–70% (hospital), 20–40% (community) — cefotetan/cefoxitin are NOT reliably active against ESBL producers
⚠️ B. fragilis group resistance to cephamycins: 15–30% (variable by centre; increasing trend)
⚠️ AmpC-producing Enterobacterales (Enterobacter, Citrobacter, Serratia): cephamycins may select for resistant mutants on therapy
ICMR AMR surveillance data (most recent) should be consulted for local resistance patterns before choosing empirical therapy for any infection where cefotetan or its alternatives are considered

4. Do NOT use cefotetan (or its Indian alternative cefoxitin) for:

⛔ MRSA infections
⛔ ESBL-producing gram-negative infections
⛔ Pseudomonas infections
⛔ Enterococcal infections
⛔ Meningitis (poor CSF penetration)
⛔ Gonorrhoea (use ceftriaxone per NACO/ICMR/WHO guidelines)
⛔ Atypical pneumonia as monotherapy

GENERAL ADULT DOSING REFERENCE TABLE

ℹ️ All doses below are for cefotetan (parenteral-only). The Indian alternative (cefoxitin) has different dosing — noted alongside each indication.

Parenteral (IV/IM) — Cefotetan Disodium:

Dose Tier	Route	Per-Dose	Frequency	Total Daily Dose	Typical Use
Mild-Moderate	IV or IM	1 g	Every 12 hours (q12h)	2 g/day	Uncomplicated UTI, mild SSTI
Moderate-Severe	IV	2 g	Every 12 hours (q12h)	4 g/day	Most infections (IAI, PID, LRTI, bone/joint, complicated UTI, surgical prophylaxis)
Severe / Life-threatening	IV	2 g	Every 12 hours (q12h) — or 3 g q12h in exceptional circumstances	4–6 g/day	Severe infections, high-inoculum polymicrobial infections
Surgical prophylaxis	IV	1–2 g	Single pre-operative dose	1–2 g (single dose)	See Indication 1 below

Mandatory Dose Format:

Starting dose: Full therapeutic dose from first administration (no loading dose; no titration for antibiotics)
Titration: Not applicable
Usual maintenance dose: 1–2 g IV q12h (indication-dependent)
Maximum dose: Max 3 g per dose (exceptional); Max 6 g per day (exceptional — rarely used in practice; standard maximum is 4 g/day for most indications)

Primary Indications (Approved / Standard)

Indication 1: SURGICAL PROPHYLAXIS — Colorectal, Gynaecological, and Clean-Contaminated Procedures

Context

Cefotetan’s primary clinical niche — and the indication most commonly encountered by Indian prescribers reading international (particularly US) guidelines — is surgical prophylaxis for procedures where both aerobic and anaerobic coverage are needed. The long half-life (~3–4.6 hours) allows a single pre-operative dose to cover most procedures without intraoperative re-dosing — a practical advantage over cefoxitin (which requires re-dosing every 2–3 hours intraoperatively).

Dosing

Route	Dose	Timing	Re-dosing	Post-Operative Continuation	Notes
IV	1–2 g (most guidelines recommend 2 g)	Within 60 minutes before skin incision (at induction of anaesthesia)	Re-dose if procedure exceeds 6 hours OR blood loss >1500 mL	⛔ Single dose preferred. Maximum 24 hours post-operatively. ⚠️ Do NOT continue prophylaxis >24 hours — no evidence of benefit; increases AMR, CDI, and NMTT-related adverse effects.	2 g dose recommended for obese patients (BMI ≥30).

Procedures Where Cefotetan Prophylaxis Is Referenced in International Guidelines

Procedure Type	Cefotetan Recommended?	Indian Alternative
Colorectal surgery (including appendectomy)	✅ Yes — cefotetan 2 g IV single dose. The combined aerobic + anaerobic coverage is the rationale.	Cefoxitin 2 g IV (re-dose q2–3h intra-op) OR Cefuroxime 1.5 g IV + Metronidazole 500 mg IV OR Amoxicillin-clavulanate 1.2 g IV
Gynaecological surgery (hysterectomy — abdominal, vaginal, laparoscopic)	✅ Yes — cefotetan 2 g IV single dose	Cefoxitin 2 g IV OR Cefazolin 2 g IV + Metronidazole 500 mg IV OR Amoxicillin-clavulanate 1.2 g IV
Caesarean section	✅ Acceptable alternative (anaerobic coverage may be beneficial for complicated C-sections)	Cefazolin 2 g IV (first-line per FOGSI/ACOG — anaerobic coverage usually not needed for routine C-section)
Head and neck surgery (clean-contaminated — mucosal incision)	✅ Acceptable	Cefuroxime 1.5 g IV + Metronidazole 500 mg IV OR Amoxicillin-clavulanate 1.2 g IV
Biliary surgery (open cholecystectomy, ERCP with intervention)	✅ Acceptable	Cefuroxime 1.5 g IV OR Cefazolin 2 g IV (add metronidazole if bile-duct manipulation)
Clean surgery (orthopaedic, cardiac, hernia, breast)	⛔ NOT appropriate — anaerobic coverage unnecessary; cefazolin is preferred	Cefazolin 2 g IV (NLEM-listed, first-line for clean surgery prophylaxis per AIIMS/ASHP guidelines)

Mandatory Clinical Notes Checklist

When to prefer cefotetan over alternatives:
- (a) Clinical scenario where cefotetan has an advantage: When a single pre-operative dose providing combined aerobic + anaerobic coverage is desired for procedures lasting up to 6 hours WITHOUT intraoperative re-dosing. Cefoxitin’s short half-life (~45–60 min) requires re-dosing every 2–3 hours intraoperatively — logistically challenging in long procedures.
- (b) This makes cefotetan a convenient first-choice for prolonged colorectal/GYN surgeries — but NOT superior in terms of spectrum or outcomes.
- © Compared against: cefoxitin (shorter t½, needs re-dosing), cefazolin + metronidazole (two-drug combination), amoxicillin-clavulanate IV (comparable coverage, but different spectrum nuances).
- ℹ️ For India: Since cefotetan is unavailable, the practical choice is cefoxitin or cefazolin + metronidazole. If the procedure is expected to be prolonged (>3 hours), the two-drug combination (cefazolin + metronidazole) may be simpler than re-dosing cefoxitin.
When NOT to use cefotetan for surgical prophylaxis:
- ⛔ Clean surgery (no anaerobic flora exposure) — use cefazolin alone
- ⛔ Suspected/confirmed MRSA colonisation — add vancomycin
- ⛔ Patient on warfarin/acenocoumarol — NMTT side chain → additive coagulopathy risk; use cefoxitin or cefazolin + metronidazole instead
- ⛔ Patient with history of disulfiram-like reactions or who may consume alcohol post-operatively within 72 hours
- ⛔ Continuation beyond 24 hours post-operatively — no benefit, increased risk
NLEM India: ❌ Cefotetan is NOT listed in NLEM India 2022. For surgical prophylaxis, NLEM-listed options include: cefazolin injection (1 g), cefuroxime injection (750 mg, 1.5 g), metronidazole injection (500 mg/100 mL).
Time to expected clinical response: Not applicable — prophylaxis, not treatment. Efficacy measured by absence of surgical site infection (SSI) at 30-day post-operative assessment.
Criteria for treatment failure: Development of SSI despite prophylaxis → obtain wound culture, initiate therapeutic antibiotics based on susceptibility. Do NOT extend prophylactic antibiotics beyond 24 hours as “extended prophylaxis” — this does not prevent SSI and promotes resistance.
Mandatory baseline investigations: Allergy history (cephalosporin/penicillin). If using cefotetan specifically: baseline PT/INR (NMTT coagulopathy risk). Not required for cefoxitin or cefazolin alternatives.
Specialist initiation: Not required — any surgeon/anaesthesiologist can prescribe surgical prophylaxis.
Indian guideline source: AIIMS Surgical Prophylaxis Protocol; NCDC Infection Control Guidelines; ASHP/IDSA/SIS Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery (2013) — Bratzler DW, et al. (international, adapted for Indian practice). API Textbook — Surgical Site Infections chapter.
Key disease-specific safety warning:
⚠️ NMTT-specific for cefotetan: If cefotetan prophylaxis is used (e.g., from imported supply), ensure the patient has NO access to alcohol-containing products (beverages, medications, tonics) for 72 hours after administration. Also check baseline PT/INR — a single prophylactic dose rarely causes clinically significant coagulopathy, but patients with pre-existing coagulopathy or liver disease are at risk.
Common dose adjustment scenarios: Renal impairment — see Renal Adjustment (Part 3); standard single prophylactic dose generally does NOT require renal adjustment. Obesity (BMI ≥30): use the 2 g dose.

Indication 2: PELVIC INFLAMMATORY DISEASE (PID) — Inpatient Treatment (CDC Regimen)

Context

Cefotetan is a named component of the CDC-recommended inpatient PID regimen (United States). This is the context in which Indian O&G specialists are most likely to encounter cefotetan — reading CDC guidelines for PID management and needing to translate them into Indian-available drugs. The CDC regimen uses cefotetan specifically because it covers the polymicrobial aetiology of PID: N. gonorrhoeae, C. trachomatis (via the doxycycline component), anaerobes (B. fragilis, Prevotella), and aerobic gram-negative rods.

CDC Inpatient PID Regimen A (Cefotetan-Based)

Drug	Route	Dose	Frequency	Duration	Notes
Cefotetan	IV	2 g	Every 12 hours (q12h)	Until clinical improvement (≥24–48 hours after fever resolution and symptom improvement) → then switch to oral step-down	Combined aerobic + anaerobic coverage
PLUS Doxycycline	IV or Oral (oral preferred — less painful, equivalent bioavailability)	100 mg	Every 12 hours (q12h)	14 days total (IV during hospitalisation → oral to complete 14 days after discharge)	Covers Chlamydia trachomatis. Oral doxycycline is preferred even during hospitalisation because IV doxycycline causes severe phlebitis and oral bioavailability is ~100%.

Oral Step-Down After IV Cefotetan-Based PID Regimen

Drug	Route	Dose	Frequency	Duration	Notes
Doxycycline	Oral	100 mg	BID	To complete 14 days total (counting from start of treatment)	Continues after IV cefotetan is stopped
± Metronidazole	Oral	500 mg	BID	To complete 14 days total	Added for enhanced anaerobic coverage (optional per CDC — recommended if tubo-ovarian abscess [TOA] present)

ℹ️ Cefotetan has NO oral formulation. The step-down from IV cefotetan is to oral doxycycline ± metronidazole — NOT to an oral cephalosporin.

Indian Alternative for Inpatient PID

CDC Regimen	Indian Equivalent
Cefotetan 2 g IV q12h + Doxycycline 100 mg oral/IV q12h	Cefoxitin 2 g IV q6h + Doxycycline 100 mg oral q12h
OR	Ceftriaxone 250 mg IM single dose (gonococcal coverage) + Doxycycline 100 mg oral BID × 14 days ± Metronidazole 500 mg oral BID × 14 days (outpatient regimen — for mild-moderate PID per CDC alternative)
OR	Amoxicillin-clavulanate 1.2 g IV q8h + Doxycycline 100 mg oral q12h (non-standard but used in Indian practice for mixed aerobic-anaerobic pelvic infections)

Mandatory Clinical Notes Checklist

When to prefer cefotetan over alternatives for PID:
- (a) Cefotetan’s advantage in PID: q12h dosing vs cefoxitin’s q6h, providing the same spectrum coverage with fewer daily IV infusions. Combined aerobic + anaerobic coverage in a single agent without needing to add metronidazole separately.
- (b) This makes cefotetan a convenient alternative to cefoxitin for inpatient PID — but NOT superior in efficacy. Clinical outcomes are equivalent.
- © Compared against: cefoxitin (q6h — more nursing workload), ceftriaxone + doxycycline ± metronidazole (outpatient alternative — no anaerobic coverage from ceftriaxone alone).
- ℹ️ For India: Use cefoxitin 2 g IV q6h + doxycycline 100 mg oral q12h as the direct substitution. If cefoxitin is unavailable at a specific institution: ampicillin-sulbactam 3 g IV q6h + doxycycline or amoxicillin-clavulanate 1.2 g IV q8h + doxycycline provide reasonable alternatives.
When NOT to use:
- ⛔ Outpatient PID (mild-moderate) — does not need IV therapy; use outpatient CDC Regimen (ceftriaxone IM single dose + doxycycline oral ± metronidazole oral)
- ⛔ Suspected gonococcal PID with known cefotetan resistance (rare, but gonococcal susceptibility to second-generation cephamycins is declining)
- ⛔ Patient on anticoagulants — NMTT coagulopathy risk; use cefoxitin or ampicillin-sulbactam instead
- ⛔ If TOA requires drainage — surgical/interventional drainage is the primary treatment; cefotetan/cefoxitin is adjunctive
NLEM India: ❌ Not listed. For PID, NLEM-listed components include: ceftriaxone injection, doxycycline, metronidazole.
Time to expected clinical response: Clinical improvement (defervescence, reduced pelvic tenderness, declining WBC/CRP) expected within 48–72 hours. If no improvement by 72 hours → reassess: imaging (TOA? other pathology?), surgical consultation, broaden antibiotics.
Treatment failure criteria: Persistent fever and pelvic pain at 72 hours, enlarging TOA on imaging, development of peritonitis, new organ dysfunction. Consider: CT/MRI pelvis, interventional drainage of TOA, switch to broader-spectrum regimen (e.g., carbapenem + clindamycin/metronidazole), and gynaecological surgical consultation.
Mandatory baseline investigations: MANDATORY: Pregnancy test (rule out ectopic pregnancy), STI screening (GC/CT NAAT — nucleic acid amplification test), pelvic ultrasound (to evaluate for TOA), CBC, CRP/ESR, HIV and syphilis screening (NACO guidelines for all PID patients). RECOMMENDED: Blood cultures if systemically unwell, endocervical swab for Gram stain/culture.
Specialist initiation: Inpatient PID management typically by O&G specialist or infectious disease physician. Not primary care.
Indian guideline source: CDC STI Treatment Guidelines 2021 (international reference — widely used in Indian O&G practice); FOGSI Guidelines on PID; API Textbook — Gynaecological Infections; ICMR NACO STI Treatment Guidelines.
Key disease-specific safety warning:
⚠️ Always rule out ectopic pregnancy before diagnosing PID — ectopic pregnancy is a life-threatening surgical emergency that can mimic PID symptoms. Pregnancy test is MANDATORY before starting any PID regimen.
⚠️ Partner notification and treatment — all sexual partners from the preceding 60 days must be tested and empirically treated for gonorrhoea and chlamydia.
Common dose adjustment scenarios: Renal impairment — adjust cefotetan per CrCl (Part 3). No hepatic adjustment for cefotetan itself, but monitor PT/INR if liver disease (NMTT risk amplification).
ℹ️ Investigation misconception flag: ℹ️ CA-125 is NOT useful for diagnosing PID — CA-125 can be elevated in PID but is non-specific (also elevated in endometriosis, ovarian malignancy, peritonitis, pregnancy). Do NOT order CA-125 as a PID diagnostic test. Diagnosis is primarily clinical (CDC clinical criteria) supplemented by imaging and microbiological testing.

Indication 3 (Combined): INTRA-ABDOMINAL INFECTIONS + URINARY TRACT INFECTIONS + SKIN AND SOFT TISSUE INFECTIONS + LOWER RESPIRATORY TRACT INFECTIONS + BONE AND JOINT INFECTIONS

Rationale for Combining

These five approved indications share ALL of the following:

(a) Identical dosing range: 1–2 g IV (or IM for less severe)
(b) Identical routes: IV (preferred) or IM
© Identical frequency: Every 12 hours (q12h)
(d) Differ ONLY in: duration of therapy, severity-based dose selection, and disease-specific clinical notes

Per the template’s Combined Indication Rule, they are presented as a single dosing entry with condition-specific notes below.

Dosing Table — All Five Indications

Route	Severity	Per-Dose	Frequency	Duration	Notes
IV (preferred for all)	Mild-Moderate	1 g	Every 12 hours (q12h)	See condition-specific notes below	For less severe presentations. Can step down to oral alternative when clinically improving.
IV	Moderate-Severe	2 g	Every 12 hours (q12h)	See condition-specific notes below	Standard dose for most hospitalised patients with these indications.
IV	Severe/Life-threatening	2–3 g	Every 12 hours (q12h)	See condition-specific notes below	Max 3 g per dose; Max 6 g per day. Rarely needed.
IM	Mild (if IV access unavailable)	1–2 g	Every 12 hours (q12h)	See condition-specific notes below	Deep IM injection. Less reliable for severe infections. IM route rarely preferred when IV access is achievable.

Condition-Specific Notes

A. Intra-Abdominal Infections (IAI) — Peritonitis, Intra-Abdominal Abscess, Perforated Viscus

Duration: 4–7 days post source control (shorter if adequate surgical source control achieved; longer for complicated cases without definitive source control). ⛔ Do NOT continue antibiotics indefinitely without re-evaluating source control.

Specific clinical notes:

When to prefer cefotetan: Single-agent coverage of both aerobic gram-negatives and anaerobes (B. fragilis) for community-acquired IAI without additional drugs. Avoids the need for cephalosporin + metronidazole two-drug regimen.
- (a) Advantage: single-agent convenience
- (b) Status: acceptable alternative, NOT first-line over metronidazole-based combinations
- © Compared against: cefuroxime + metronidazole, ampicillin-sulbactam, amoxicillin-clavulanate, piperacillin-tazobactam (for severe/healthcare-associated)
- ℹ️ Indian alternative: Cefoxitin 2 g IV q6h (single-agent cephamycin) OR Cefuroxime 1.5 g IV q8h + Metronidazole 500 mg IV q8h (NLEM-listed combination) OR Ampicillin-sulbactam 3 g IV q6h OR Amoxicillin-clavulanate 1.2 g IV q8h
When NOT to use: ⛔ Healthcare-associated IAI (likely MDR gram-negatives — need piperacillin-tazobactam or carbapenem). ⛔ ESBL-producing organisms documented. ⛔ Perforated upper GI (minimal anaerobic burden — simpler regimen adequate). ⛔ Tertiary peritonitis (ICU-level care with broader-spectrum regimens).
NLEM India: ❌ Not listed.
Expected response: Defervescence, improvement in abdominal signs, declining WBC/CRP within 48–72 hours. If no improvement → re-image (CT abdomen for undrained collection), consider surgical re-intervention, broaden antibiotics.
Culture guidance: RECOMMENDED — peritoneal fluid culture (at time of surgery/drainage) to guide de-escalation. Blood cultures if septic.
Indian guideline source: API Textbook — Peritonitis chapter; ICMR AMR Guidelines 2019; SIS/IDSA Intra-abdominal Infection Guidelines 2010 (adapted for Indian practice).
Key safety warning: ⚠️ Source control (surgery/drainage) is the cornerstone of IAI management. Antibiotics without source control will fail. ⚠️ NMTT risk: post-operative cefotetan use in patients who are NPO, malnourished, or have liver disease → high coagulopathy risk. Monitor PT/INR. Vitamin K₁ 10 mg prophylaxis recommended.

B. Urinary Tract Infections (UTI) — Complicated

Duration: 10–14 days total (IV ± oral step-down). Uncomplicated cystitis does NOT require IV cefotetan.

Specific clinical notes:

When to prefer: ONLY for culture-confirmed susceptible organisms causing complicated UTI (pyelonephritis, urosepsis) when an IV agent with combined aerobic + anaerobic coverage is desired (e.g., suspected polymicrobial UTI in catheterised patients with concomitant intra-abdominal pathology).
- (a) Advantage: combined coverage; q12h convenience
- (b) Status: NOT first-line for any UTI indication
- © Compared against: IV ceftriaxone (broader gram-negative, NLEM-listed), IV amoxicillin-clavulanate, oral nitrofurantoin/fosfomycin (for uncomplicated)
- ℹ️ Indian alternative: IV ceftriaxone 1–2 g q24h (NLEM, once-daily, widely available) OR IV amoxicillin-clavulanate 1.2 g q8h (if enterococcal coverage also desired)
⚠️ India-specific ESBL limitation: Do NOT use cefotetan (or any cephamycin) empirically for UTI in India — ESBL prevalence among uropathogens is 20–70%. Urine C&S MANDATORY before starting.
NLEM India: ❌ Not listed. For UTI: NLEM-listed options include ceftriaxone (injection), nitrofurantoin, amoxicillin.
Culture guidance: MANDATORY — urine C&S before starting treatment for any UTI indication.

C. Skin and Soft Tissue Infections (SSTI) — Moderate to Severe, Mixed Aerobic-Anaerobic

Duration: 7–14 days (depending on severity and response). Step down to oral when clinically improving.

Specific clinical notes:

When to prefer: Mixed aerobic-anaerobic SSTIs (e.g., diabetic foot infection [non-severe, non-ischaemic], post-surgical wound infection with anaerobic component, bite wounds, perianal abscess) where a single IV agent with combined coverage is desired.
- (a) Advantage: single-agent coverage of MSSA + anaerobes
- (b) Status: acceptable alternative for non-severe mixed SSTIs; NOT first-line
- © Compared against: ampicillin-sulbactam (better enterococcal coverage for diabetic foot), amoxicillin-clavulanate IV (NLEM-listed, step-down available), piperacillin-tazobactam (for severe/healthcare-associated)
- ℹ️ Indian alternative: Ampicillin-sulbactam 3 g IV q6h OR Amoxicillin-clavulanate 1.2 g IV q8h (NLEM-listed, covers enterococci — important in diabetic foot) OR Cefazolin + Metronidazole OR Cefoxitin 2 g IV q6h
When NOT to use: ⛔ MRSA SSTI — cefotetan is inactive (use vancomycin, linezolid, or cotrimoxazole). ⛔ Necrotising fasciitis — surgical emergency requiring broader-spectrum IV antibiotics (carbapenem + clindamycin + vancomycin). ⛔ Pure gram-positive SSTIs (non-diabetic cellulitis) — cefazolin or cloxacillin is more appropriate and narrower-spectrum.
NLEM India: ❌ Not listed.

D. Lower Respiratory Tract Infections (LRTI) — Community-Acquired Pneumonia, Aspiration Pneumonia

Duration: 5–7 days (non-severe CAP); 7–14 days (aspiration pneumonia, lung abscess).

Specific clinical notes:

When to prefer: Aspiration pneumonia where anaerobic coverage is specifically needed alongside aerobic gram-negative coverage. ⛔ NOT for non-severe CAP (use cefuroxime, amoxicillin-clavulanate, or ceftriaxone — all NLEM-listed).
- (a) Advantage: single-agent aerobic + anaerobic LRTI coverage (aspiration pneumonia)
- (b) Status: acceptable alternative for aspiration pneumonia
- © Compared against: ampicillin-sulbactam IV (standard for aspiration), ceftriaxone + metronidazole, amoxicillin-clavulanate IV
- ℹ️ Indian alternative: Ampicillin-sulbactam 3 g IV q6h (standard for aspiration pneumonia in India) OR Amoxicillin-clavulanate 1.2 g IV q8h OR Ceftriaxone 2 g IV q24h + Metronidazole 500 mg IV q8h
⚠️ India-specific: Always consider tuberculosis in non-resolving pneumonia — obtain sputum AFB smear and GeneXpert. Do NOT attribute non-resolving pneumonia to antibiotic failure without ruling out TB.
NLEM India: ❌ Not listed.

E. Bone and Joint Infections — Osteomyelitis, Septic Arthritis

Duration: Osteomyelitis: 4–6 weeks (total IV + oral). Septic arthritis: 2–4 weeks. Cefotetan is rarely the drug of choice for bone/joint infections — used only when polymicrobial aetiology with anaerobic component is documented.

Specific clinical notes:

When to prefer: Culture-confirmed polymicrobial bone/joint infection with susceptible aerobic AND anaerobic organisms. NOT empirical first-line.
- (a) Advantage: combined coverage for polymicrobial bone/joint infection
- (b) Status: NOT first-line — reserve for culture-directed use
- © Compared against: cefazolin IV (MSSA osteomyelitis — first-line), cloxacillin IV, ceftriaxone IV, linezolid (if MRSA)
- ℹ️ Indian alternative: Cefoxitin 2 g IV q6h (culture-directed) OR pathogen-directed monotherapy based on culture (cefazolin for MSSA, ceftriaxone for susceptible gram-negatives)
⛔ NOT for MRSA bone/joint infections. ⛔ NOT empirical first-line for any bone/joint infection.
NLEM India: ❌ Not listed.

IV-to-Oral Step-Down Criteria (All Indications)

ℹ️ Cefotetan has NO oral formulation. Step-down from IV cefotetan requires switching to a DIFFERENT oral antibiotic. The choice of oral step-down agent depends on the indication and culture results.

Indication	Oral Step-Down Options (Culture-Guided Where Possible)
Intra-abdominal infections	Amoxicillin-clavulanate 625 mg TDS or Ciprofloxacin 500 mg BID + Metronidazole 400 mg TDS
PID	Doxycycline 100 mg BID ± Metronidazole 500 mg BID (to complete 14 days)
UTI	Culture-guided: oral cephalosporin (cefuroxime axetil, cefixime), cotrimoxazole, or fluoroquinolone
SSTI	Amoxicillin-clavulanate 625 mg TDS or Culture-guided oral agent
LRTI	Amoxicillin-clavulanate 625 mg TDS ± Metronidazole (aspiration)
Bone/joint	Culture-guided oral agent (often requires prolonged oral therapy)

Step-down criteria (applicable to ALL indications):

✅ Clinically improving (reduced fever, pain, inflammatory markers)
✅ Afebrile for ≥24–48 hours
✅ Tolerating oral medications without vomiting
✅ Functioning GI tract (no ileus, no high-output fistula)
✅ No ongoing sepsis or haemodynamic instability
✅ No undrained collection requiring source control
✅ WBC trending toward normal
✅ Identified organism susceptible to the proposed oral agent (if culture-directed)

Secondary Indications — Adults Only (Off-label, if any)

Off-Label Indication 1: SPONTANEOUS BACTERIAL PERITONITIS (SBP) — Empirical

Status: OFF-LABEL

Context: SBP in cirrhotic patients is conventionally treated with IV ceftriaxone (first-line per API Textbook and AASLD guidelines) or IV cefotaxime. Cephamycins (cefotetan, cefoxitin) are NOT standard for SBP — the added anaerobic coverage is unnecessary (SBP is typically monomicrobial with aerobic gram-negatives or streptococci, NOT anaerobes). Including this entry to explicitly state that cefotetan is NOT appropriate for SBP despite being used for other intra-abdominal infections.

⛔ NOT recommended for SBP. Use IV ceftriaxone 2 g q24h or IV cefotaxime 2 g q8h (NLEM-listed, better evidence, superior gram-negative coverage for SBP pathogens).
Evidence quality: Not applicable — no evidence supports cefotetan for SBP.
Clearly marked: OFF-LABEL — NOT recommended.

Off-Label Indication 2: SURGICAL PROPHYLAXIS FOR EMERGENCY LAPAROTOMY (Penetrating Abdominal Trauma)

Status: OFF-LABEL but accepted standard practice internationally

Context: International trauma surgery guidelines (EAST — Eastern Association for the Surgery of Trauma) recommend cephamycin-based prophylaxis (cefotetan or cefoxitin) for penetrating abdominal trauma with hollow viscus injury — providing combined aerobic + anaerobic coverage. Duration: single dose to 24 hours maximum.

Route	Dose	Duration	Notes
IV	2 g	Single pre-operative dose → continue q12h for maximum 24 hours	⛔ Do NOT continue >24 hours. If infection established: switch to therapeutic dosing and duration.

Evidence quality: Moderate (multiple trauma surgery RCTs and meta-analyses support ≤24 hours of prophylactic antibiotics for penetrating abdominal trauma; cephamycins are one recommended class)
Indian alternative: Cefoxitin 2 g IV q6h × ≤24 hours OR Cefuroxime 1.5 g IV + Metronidazole 500 mg IV (single pre-op dose → ≤24 hours)
Indian source: AIIMS Trauma Surgery protocols; adapted from EAST guidelines.
Clearly marked: OFF-LABEL but accepted standard practice internationally

MISSED DOSE / DELAYED DOSE GUIDANCE

Dosing Frequency Context

Cefotetan is administered every 12 hours (q12h) — i.e., twice daily, typically by nursing staff in a hospital setting. The drug is NOT used as an outpatient self-administered medication (parenteral-only, hospital-use drug).

For q12h (Twice-Daily) Dosing — Hospital Setting

Situation	Action
Dose delayed <4 hours	Administer immediately. Re-space subsequent doses to maintain q12h intervals from the delayed dose.
Dose delayed 4–6 hours	Administer immediately. Inform treating physician. Resume regular q12h schedule from the delayed dose timing.
Dose delayed >6 hours	Administer immediately. Inform treating physician. ⚠️ For serious infections (IAI, severe PID): a >6-hour gap with cefotetan’s ~3–4.6 hour half-life means serum levels may have fallen to subtherapeutic for 2–3 hours. Document the delay. Resume q12h schedule. If multiple delays in a 24-hour period → reassess: is IV access reliable? Is the infusion regimen being followed?
Dose entirely missed (>10 hours late)	Administer the next dose at its scheduled time. Do NOT double the dose. Inform physician. Document.

For Surgical Prophylaxis

Pre-operative dose missed: If recognised before incision → give immediately (even if within <30 minutes of incision — some tissue levels are better than none). If recognised after incision → give ASAP — late prophylaxis provides some benefit. Document timing error.
Intraoperative re-dosing missed: If procedure exceeded 6 hours and re-dosing not given → administer at recognition. If recognised only at end of surgery → give as post-operative dose.

Prolonged Non-Adherence / Drug Holiday Guidance

Not applicable — cefotetan is a hospital-administered parenteral antibiotic. Dose scheduling is under nursing staff control, not patient self-administration. Missed doses reflect hospital process failures, not patient adherence issues.

No rebound effects or withdrawal syndrome.
No immunogenicity concern (not a biologic).
No re-titration needed — resume at full dose after any delay.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

ℹ️ Availability caveat: This section is provided for reference. Since cefotetan is not marketed in India, Indian nursing staff are unlikely to administer it unless an imported supply is available at a specific institution. The comparable cephamycin available in India (cefoxitin) has its own reconstitution/administration profile and should be referenced separately.

A. RECONSTITUTION — Cefotetan Disodium Powder for Injection

For IV Bolus (Slow IV Push)

Vial Size	Diluent	Volume to Add	Approximate Final Volume	Approximate Concentration
1 g	Sterile Water for Injection (SWFI)	10 mL	~10.5 mL	~95 mg/mL
2 g	SWFI	10–20 mL	~11–21 mL	~95–182 mg/mL

For IM Injection

Vial Size	Diluent	Volume to Add	Approximate Final Volume	Approximate Concentration
1 g	SWFI, NS, 0.5% Lidocaine (Lignocaine) injection, or 1% Lidocaine injection	2 mL	~2.5 mL	~400 mg/mL
2 g	Same	3 mL	~4 mL	~500 mg/mL

⚠️ Lidocaine-reconstituted solutions: Use ONLY for IM injection — ⛔ NEVER for IV administration.

💡 IM cefotetan is moderately painful. Reconstitution with 0.5–1% lidocaine (without adrenaline) is recommended to reduce injection-site pain — standard practice for many parenteral cephalosporins/cephamycins.

B. FURTHER DILUTION FOR IV INFUSION

Parameter	Details
Compatible IV fluids	✅ Normal Saline (0.9% NaCl) — preferred. ✅ Dextrose 5% (D5W). ✅ Ringer’s Lactate. ✅ Dextrose-Saline (DNS).
Recommended dilution volume	50–100 mL for intermittent infusion (adults).
Final concentration range	10–40 mg/mL (typical).
Incompatible solutions	⛔ Aminoglycosides (gentamicin, amikacin, tobramycin) — physical and chemical incompatibility. Do NOT mix in the same IV bag or line. ⛔ Tetracyclines (heparin — check institutional data).

C. RATE OF ADMINISTRATION

Method	Rate	Notes
Slow IV Injection (Bolus/Push)	Over 3–5 minutes	Acceptable for doses up to 2 g. Dilute in ≥10 mL SWFI or NS.
Intermittent IV Infusion	Over 20–60 minutes	PREFERRED method — reduces vein irritation. Dilute in 50–100 mL compatible fluid.
Infusion pump	Recommended for precision delivery in ICU settings.	Not mandatory for ward administration if gravity infusion is standard.

D. STABILITY AFTER RECONSTITUTION

Condition	In SWFI/NS	In D5W
Room temperature (25°C)	24 hours	24 hours
Refrigerated (2–8°C)	96 hours (4 days)	96 hours (4 days)
Protected from light?	Not mandatory — cefotetan is not significantly photosensitive.	Same
Frozen (-20°C)	Pre-mixed frozen solutions (Galaxy container): thaw at room temperature, use within 24 hours after thawing. Do NOT refreeze. Reconstituted solutions from dry powder: can be frozen for up to 1 week — thaw before use, use within 24 hours.	Same

ℹ️ Stability advantage over cefoxitin: Reconstituted cefotetan is stable for 24 hours at room temperature and 96 hours refrigerated — significantly longer than cefoxitin’s 6–24 hours at RT and 48 hours refrigerated. This allows batch preparation if multiple doses are anticipated.

E. MULTI-DOSE VIAL HANDLING

Not applicable — cefotetan vials are single-dose, preservative-free. Once reconstituted, use for a single patient. Discard any unused portion.

F. Y-SITE / LINE COMPATIBILITY

Compatible (Y-site — verify institutional data)	Incompatible — Do NOT Mix
✅ Normal Saline, Dextrose 5%, Ringer’s Lactate	⛔ Aminoglycosides (gentamicin, amikacin, tobramycin) — inactivation of BOTH drugs. Administer through separate IV lines or flush with ≥20 mL NS between drugs.
✅ Heparin (Y-site — at standard concentrations)	⛔ Tetracyclines — reported incompatibility
✅ Morphine, fentanyl (Y-site — verify)	⛔ Vancomycin — possible precipitate; flush between
✅ Metronidazole IV (generally compatible)	⛔ Blood products, TPN, lipid emulsions
✅ Famotidine	⛔ Promethazine — physical incompatibility

⚠️ Critical nursing note for cefotetan + aminoglycoside: If both drugs are prescribed concurrently (e.g., cefotetan + gentamicin for severe IAI — though this combination is uncommon), administer through separate IV lines or flush with ≥20 mL NS between drugs. Do NOT mix in the same infusion bag or syringe. In vivo, the combination provides additive/synergistic killing — they are compatible in the patient, just not in the same IV tubing/bag.

G. SPECIAL ADMINISTRATION NOTES

Topic	Details
IM injection	Deep gluteal muscle (upper outer quadrant — adults) or vastus lateralis (anterolateral thigh — paediatric). Max IM volume per site: 2–3 mL (adults), 1–2 mL (children). Reconstitute with lidocaine to reduce pain.
Phlebitis risk	Moderate (~3–5%). Dilute adequately, infuse over ≥20 minutes, rotate IV sites every 48–72 hours.
Extravasation	Low risk — cefotetan is NOT a vesicant. If extravasation occurs: stop infusion, apply warm compress, monitor. No specific antidote.
Flush line	Flush with 10–20 mL NS before and after cefotetan, especially when aminoglycosides or vancomycin are co-infused.
Filter	Standard IV set — no special in-line filter required.
Colour	Solution ranges from colourless to light yellow. ⛔ Discard if dark yellow/brown or precipitated. Slight darkening does not indicate loss of potency within the stability period.
Sodium content	Each 1 g of cefotetan disodium contains approximately 3.5 mEq (80 mg) of sodium. At maximum dosing (6 g/day → ~21 mEq/day of sodium from drug alone) — relevant for sodium-restricted patients (CHF, cirrhosis).

H. STORAGE

Form	Storage Conditions
Dry powder (vials — before reconstitution)	Store at room temperature (20–25°C). Protect from light. Protect from moisture. No refrigeration needed for dry powder.
Reconstituted solution	See Stability table above: RT 24 hrs, refrigerated 96 hrs.
Premixed frozen solutions	Store at or below -20°C. Thaw at room temperature (do NOT heat). Use within 24 hours of thawing. Do NOT refreeze.

I. COLD-CHAIN GUIDANCE

Not applicable for dry powder formulations — room temperature storage. Premixed frozen solutions require freezer storage (-20°C) during transport and storage, with controlled thawing before use. This formulation type is unlikely to be encountered in Indian hospitals.

PAEDIATRIC DOSING (Specialist Only)

⚠️ CRITICAL AVAILABILITY AND SAFETY CAVEATS

Cefotetan is NOT marketed in India. Paediatric dosing below is provided for reference only — Indian paediatricians encountering cefotetan recommendations in international literature should use cefoxitin (the available Indian cephamycin) or other listed alternatives.
⚠️ NMTT side chain — heightened paediatric concern: The N-methylthiotetrazole (NMTT) side chain of cefotetan poses a particularly significant risk in paediatric patients due to:
- Neonates and young infants have lower vitamin K stores (especially if breastfed exclusively without vitamin K prophylaxis at birth)
- Paediatric patients are more susceptible to antibiotic-associated disruption of vitamin K–producing gut flora
- Nutritional status may be suboptimal in hospitalised Indian children
- Concurrent NPO status (perioperative, critically ill) eliminates dietary vitamin K intake
- Coagulopathy from cefotetan’s NMTT side chain in a paediatric surgical patient can be catastrophic — postoperative haemorrhage risk
💡 For these reasons, cefoxitin (no NMTT side chain) is STRONGLY preferred over cefotetan in paediatric practice. If cefotetan is the only available cephamycin, prophylactic vitamin K₁ supplementation is MANDATORY in all paediatric patients.
⚠️ Disulfiram-like reaction — paediatric relevance: While alcohol consumption is not typically a paediatric concern, many paediatric medications in India contain alcohol as an excipient (cough syrups, tonics, some oral suspensions, homoeopathic preparations). Nursing staff and caregivers must be warned to avoid ALL alcohol-containing medications during cefotetan therapy and for 72 hours after the last dose.

General Notes — Paediatric

Safety Monitoring Requirements Specific to Paediatric Use

Parameter	Requirement
Allergy history	⚠️ MANDATORY — beta-lactam allergy history (child AND family history of drug allergy/atopy). Classify per Penicillin Allergy Decision framework.
PT/INR monitoring	⚠️ MANDATORY for cefotetan — check baseline PT/INR before starting, and at day 3 and day 5 of therapy (or more frequently if risk factors). NOT required for cefoxitin (no NMTT side chain).
Vitamin K₁ prophylaxis	⚠️ MANDATORY for all paediatric patients receiving cefotetan — Vitamin K₁ (phytomenadione) 1–5 mg IV/IM at initiation of therapy (dose based on age/weight), then 1–5 mg twice weekly for the duration of cefotetan therapy. This is NOT needed for cefoxitin.
Renal function	RECOMMENDED — serum creatinine at baseline (calculate eGFR using bedside Schwartz formula). Cefotetan is ~50–80% renally eliminated; dose adjustment needed if eGFR <30 mL/min/1.73 m².
Diarrhoea / CDI	Monitor for antibiotic-associated diarrhoea. If severe/bloody → test for C. difficile toxin (though CDI is less common in children <2 years than in adults).
Bleeding assessment	Daily clinical assessment: bruising, oozing from IV/surgical sites, petechiae, gum bleeding, blood in stool/urine. Promptly investigate any unexplained bleeding.

Minimum Age Limits

Age Group	Cefotetan Use Status	Notes
Neonates (<28 days)	⚠️ Very limited data. See Neonatal section below.	NICU supervision only. NMTT risk is highest in this age group. Cefoxitin is strongly preferred.
Infants 1–12 months	⚠️ Limited data. May be used under specialist supervision.	Mandatory vitamin K₁ supplementation. Weight-based dosing.
Children 1–12 years	✅ Established weight-based dosing available.	Standard paediatric doses with vitamin K₁ supplementation.
Adolescents ≥12 years or ≥40 kg	Use adult dosing (1–2 g IV q12h).	Adult ceiling doses apply.

Minimum Weight

No specific minimum weight requirement — dosing is weight-based (mg/kg). However, for infants <5 kg, pharmacokinetic data is extremely limited. In these patients, cefoxitin (with better-established neonatal/infant dosing) or ampicillin + gentamicin (standard neonatal empirical therapy) should be preferred.

Formulation Suitability for Children

Formulation	Suitability
IV injection (1 g, 2 g vials)	✅ Suitable — can be reconstituted and diluted to any concentration for weight-based paediatric dosing. Administer via slow IV push (3–5 min) or intermittent infusion (20–30 min). Use syringe pump for precise delivery in infants and young children.
IM injection	⚠️ Acceptable when IV access is unavailable. Painful — reconstitute with 0.5% lidocaine to reduce pain. Maximum IM volume per site: 0.5 mL (neonates), 1 mL (infants), 2 mL (older children). Use vastus lateralis (anterolateral thigh) in infants and young children.
Oral formulation	⛔ Does NOT exist. Cefotetan is parenteral-only. No oral suspension or tablet is available. If oral step-down is needed: switch to a different oral antibiotic.

Palatability

Not applicable — no oral formulation. All cefotetan administration is via IV or IM injection under nursing/medical supervision.

Age-Specific Pharmacokinetic Differences

Age Group	PK Difference	Clinical Implication
Neonates (preterm and term)	Significantly prolonged half-life (~5–8 hours estimated — formal neonatal PK data very limited) due to immature renal function and larger Vd per kg. Protein binding may be lower (lower albumin in neonates → higher free drug fraction).	Extended dosing intervals (q12–24h). Higher free drug fraction may provide better bactericidal activity but also increases NMTT-related toxicity risk. ⚠️ NMTT-related coagulopathy risk is HIGHEST in this group due to: low vitamin K stores, immature hepatic vitamin K cycling, gut flora not yet established.
Infants 1–12 months	Half-life ~2–3 hours (approaching adult values as renal function matures by ~6–12 months).	Standard q12h dosing interval. Monitor renal function. Vitamin K₁ supplementation mandatory.
Children 1–12 years	Half-life ~1.5–3 hours (may be shorter than adults due to higher GFR per kg in children).	Standard q12h dosing interval. Weight-based dosing: 20–40 mg/kg/dose q12h.
Adolescents ≥12 years or ≥40 kg	PK approaches adult values.	Use adult dosing: 1–2 g IV q12h.

NEONATAL DOSING

⚠️ Neonatal Use — NICU Supervision Only

ℹ️ Neonatal dosing data for cefotetan is EXTREMELY LIMITED. There are no validated neonatal dosing regimens from large PK studies. The dose below is extrapolated from limited pharmacokinetic data (small case series, PK extrapolation from adult/paediatric data adjusted for neonatal renal immaturity) and should be used only under neonatologist supervision in exceptional circumstances.

⚠️ Cefotetan is NOT a preferred agent for neonatal infections. The standard empirical neonatal sepsis regimen per NNF India, IAP, and WHO is IV ampicillin + IV gentamicin. Cefoxitin (the available Indian cephamycin) is preferred over cefotetan for neonatal infections requiring cephamycin coverage because:

Cefoxitin has NO NMTT side chain → no coagulopathy risk → critically important in neonates
Cefoxitin has better-established neonatal dosing data
Cefoxitin is available in India

When Cefotetan Might Be Considered in Neonates (Exceptional Circumstances Only)

Culture-confirmed intra-abdominal infection caused by organisms susceptible ONLY to cefotetan (and not to cefoxitin, ampicillin-sulbactam, or other available agents) — extremely unlikely scenario
International transfer of a neonate already on cefotetan therapy where continuation is deemed necessary for a short period before switching to an Indian-available alternative

Extrapolated Neonatal Dosing — USE WITH EXTREME CAUTION

Gestational Age / Postnatal Age	Dose	Interval	Route	Maximum Daily Dose	MANDATORY Additional Orders
Preterm (<37 weeks GA), PNA 0–14 days	20 mg/kg/dose	Every 12–24 hours (q12–24h) — use q24h for extreme prematurity (<32 weeks GA)	IV only (slow push over 3–5 min or infusion over 20–30 min)	40 mg/kg/day	⚠️ Vitamin K₁ 0.5–1 mg IV/IM at initiation, then 0.5–1 mg every 3 days. PT/INR at baseline, day 2, day 5, then every 3 days. Daily bleeding assessment.
Term (≥37 weeks GA), PNA 0–14 days	20–30 mg/kg/dose	Every 12 hours (q12h)	IV only	60 mg/kg/day	Same mandatory vitamin K₁ and PT/INR monitoring as above
Term, PNA 15–28 days	20–30 mg/kg/dose	Every 12 hours (q12h)	IV only	60 mg/kg/day	Same

Based on extrapolation from limited pharmacokinetic data; no validated neonatal dosing regimen exists. NICU supervision only. Cefotetan is NOT a preferred neonatal antibiotic — it is an exceptional/last-resort option when no alternative cephamycin or appropriate beta-lactam/beta-lactamase inhibitor is available.

⛔ Do NOT use for empirical neonatal sepsis — standard empirical EONS/LONS therapy is ampicillin + gentamicin (NNF India, IAP, WHO).

PAEDIATRIC DOSING REFERENCE TABLE

Parenteral (IV/IM) — Cefotetan Disodium

Dosing Tier	Dose	Frequency	Typical Use	Maximum Absolute Dose (Adult Ceiling)
Standard (most indications)	20–40 mg/kg/dose	Every 12 hours (q12h)	IAI, UTI, SSTI, LRTI, pelvic infections	Max 2 g per dose; Max 4 g per day (standard adult ceiling). Exceptional: 3 g per dose / 6 g per day — rarely needed in paediatrics.
Surgical prophylaxis	30–40 mg/kg (single dose)	Single pre-operative dose	Colorectal, GYN paediatric surgery (rare)	Max 2 g (single dose)
Mild infections	20 mg/kg/dose	Every 12 hours (q12h)	Uncomplicated UTI (culture-confirmed), mild SSTI	Max 1 g per dose

Primary Indications — Paediatric (Approved / Standard)

Paediatric Indication 1: INTRA-ABDOMINAL INFECTIONS — Community-Acquired, Culture-Directed

Weight-Based Dosing Table

Age Group	Dose	Frequency	Duration	Notes
1 month – 12 years	40 mg/kg/dose	Every 12 hours (q12h)	4–7 days post source control	⚠️ MANDATORY: Vitamin K₁ supplementation + PT/INR monitoring (see General Notes).
≥12 years or ≥40 kg	2 g (adult dose)	Every 12 hours (q12h)	4–7 days post source control	Adult dosing. Same NMTT precautions.

Worked Dosing Example

Patient: 6-year-old, 20 kg, with perforated appendicitis requiring appendectomy + IV antibiotics.

Dose calculation: 40 mg/kg/dose = 40 × 20 = 800 mg per dose q12h

Using 1 g vial: Reconstitute 1 g in 10 mL SWFI (concentration ~95 mg/mL). Draw 8.4 mL = ~800 mg.
Dilute in 50 mL NS, infuse over 20–30 minutes.

Mandatory concurrent order: Vitamin K₁ 2 mg IV at initiation. PT/INR at baseline, day 3, day 5.

Mandatory Clinical Notes (Paediatric IAI)

When to prefer cefotetan: Only when a single-agent cephamycin providing aerobic + anaerobic coverage is specifically needed AND cefoxitin is unavailable AND no alternative regimen is feasible. This is an extremely unlikely clinical scenario in Indian paediatric practice.
- ℹ️ Indian alternative (STRONGLY preferred): Cefoxitin 25–40 mg/kg/dose IV q6h (no NMTT risk) OR Cefuroxime 25–50 mg/kg/dose IV q8h + Metronidazole 7.5 mg/kg/dose IV q8h (both NLEM-listed) OR Ampicillin-sulbactam OR Piperacillin-tazobactam (for severe/healthcare-associated IAI)
When NOT to use: ⛔ Empirical neonatal necrotising enterocolitis (NEC) — use meropenem + vancomycin or piperacillin-tazobactam + vancomycin. ⛔ Healthcare-associated IAI (likely MDR organisms). ⛔ ESBL-producing organisms documented. ⛔ When cefoxitin is available (preferred — no NMTT risk).
NLEM India: ❌ Not listed.
Expected response: 48–72 hours. If no improvement → re-image (CT/USS for undrained collection), reassess surgical source control.
Culture guidance: RECOMMENDED — peritoneal fluid culture at surgery.
Indian guideline source: IAP guidelines on paediatric abdominal infections; API Textbook — Peritonitis; SIS/IDSA IAI guidelines (adapted).
Key safety warning: ⚠️ Vitamin K₁ supplementation is NON-NEGOTIABLE in any paediatric patient receiving cefotetan. Post-operative coagulopathy in a child with recent abdominal surgery can be life-threatening. If cefotetan is used: order vitamin K₁ concurrently on the prescription chart — do NOT rely on a separate verbal order.

Paediatric Indication 2: SURGICAL PROPHYLAXIS — Colorectal / GYN Paediatric Surgery

Age Group	Dose	Timing	Re-dosing	Post-Op Duration
1 month – 12 years	30–40 mg/kg (max 2 g)	Within 60 minutes before incision	Re-dose if procedure >6 hours or blood loss >25 mL/kg	⛔ Single dose preferred. Maximum 24 hours.
≥12 years or ≥40 kg	2 g (adult dose)	Same	Same	Same

Clinical Notes

ℹ️ Indian alternative (preferred): Cefoxitin 30–40 mg/kg IV (re-dose q2–3h intra-op) OR Cefazolin 30 mg/kg IV + Metronidazole 7.5 mg/kg IV (for colorectal/GYN procedures needing anaerobic coverage)
For clean paediatric surgery (orthopaedic hardware): ⛔ Do NOT use cefotetan — use cefazolin alone (narrower spectrum, better MSSA coverage, no NMTT risk)
⚠️ Even for single-dose prophylaxis: consider vitamin K₁ 1–2 mg IV if the child has risk factors for vitamin K deficiency (malnutrition, exclusive breastfeeding without vitamin K at birth, liver disease, prolonged NPO)

Paediatric Indication 3: URINARY TRACT INFECTIONS — Complicated, Culture-Directed

Age Group	Dose	Frequency	Duration	Notes
1 month – 12 years	20–40 mg/kg/dose	Every 12 hours (q12h)	10–14 days total (IV → oral step-down)	⚠️ ONLY when culture confirms susceptible, non-ESBL organism.
≥12 years or ≥40 kg	1–2 g (adult dose)	q12h	Same	Same

ℹ️ Indian alternative (preferred): IV ceftriaxone 50–75 mg/kg q24h (NLEM-listed, once-daily, no NMTT risk) OR IV cefoxitin 25–40 mg/kg q6h (if cephamycin specifically needed)
Culture guidance: MANDATORY — urine C&S before starting. ESBL prevalence in Indian paediatric uropathogens is rising.
NLEM India: ❌ Not listed. Ceftriaxone injection is NLEM-listed.

Paediatric Indication 4: SKIN AND SOFT TISSUE INFECTIONS — Moderate, Mixed Aerobic-Anaerobic

Age Group	Dose	Frequency	Duration	Notes
1 month – 12 years	20–40 mg/kg/dose	Every 12 hours (q12h)	7–10 days	For community-acquired mixed SSTIs. NOT for MRSA.
≥12 years or ≥40 kg	1–2 g (adult dose)	q12h	Same	Same

ℹ️ Indian alternative (preferred): Amoxicillin-clavulanate 30 mg/kg/dose IV q8h (amoxicillin component; NLEM-listed) OR Ampicillin-sulbactam OR Cefoxitin 25–40 mg/kg q6h
⛔ NOT for MRSA SSTI — use cotrimoxazole or clindamycin
⛔ NOT for bite wounds as monotherapy in paediatrics — amoxicillin-clavulanate is preferred (enterococcal and Pasteurella coverage)

Secondary Indications — Paediatric (Off-label, if any)

ℹ️ No well-established off-label paediatric indications for cefotetan. Given that the drug is unavailable in India and has significant NMTT-related safety concerns in children, off-label paediatric use is not recommended.

No established paediatric off-label indication. Use only under specialist supervision in exceptional circumstances when all Indian-available alternatives are contraindicated or ineffective based on culture data.
Evidence quality: Very weak (case reports only; no paediatric off-label RCTs)
Clearly marked: OFF-LABEL — not recommended for routine paediatric use

RENAL ADJUSTMENT

eGFR Formula Specification

Dosing adjustments below are based on Creatinine Clearance (CrCl) by Cockcroft-Gault (as original pharmacokinetic studies used this method). CKD-EPI eGFR may be used as a practical substitute in adults but may overestimate renal function in elderly, low-muscle-mass, and vegetarian Indian patients.

For paediatric renal adjustment: use the bedside Schwartz formula (CKiD equation) for eGFR estimation.

Rationale for Renal Adjustment

Cefotetan is 50–80% renally eliminated unchanged. Half-life prolongs dramatically with declining renal function:

CrCl (mL/min)	Approximate t½
>50	~3–4.6 hours (normal)
30–50	~5–7 hours
10–30	~10 hours
<10	~13–25 hours
Haemodialysis (anuric)	~13–25 hours (between HD)

⚠️ Additional NMTT concern in renal impairment: Drug accumulation → NMTT side chain metabolite accumulation → amplified coagulopathy and disulfiram-reaction risk. Vitamin K₁ prophylaxis and PT/INR monitoring are even more critical in renally impaired patients.

Adult Renal Dosing Adjustment Table

CrCl (mL/min)	Dose	Interval	Notes
>30	✅ No adjustment. Standard dosing: 1–2 g IV q12h.	q12h	Full dose, standard interval.
10–30	Standard per-dose amount (1–2 g)	Extend interval to every 24 hours (q24h)	⚠️ Significant half-life prolongation (~10 hours). NMTT accumulation risk → MANDATORY vitamin K₁ prophylaxis and PT/INR monitoring every 2–3 days.
<10 (non-dialysis)	Standard per-dose amount (1–2 g)	Extend interval to every 48 hours (q48h)	⚠️ Marked accumulation. t½ ~13–25 hours. NMTT coagulopathy risk very high. Monitor PT/INR daily. Consider alternative agent if prolonged therapy anticipated.
Haemodialysis (HD)	Standard dose (1–2 g)	Every 24 hours on non-HD days. On HD days: administer the dose after the HD session (to avoid removal — though only ~6–10% is removed).	ℹ️ Cefotetan is minimally dialysable due to high protein binding (~76–91%). Only ~6–10% removed per standard 4-hour HD session → supplemental post-HD dosing is generally NOT required. However, some sources suggest a supplemental 50% dose after prolonged (>4 hours) or high-efficiency HD sessions. Consult nephrology.
Peritoneal dialysis (PD)	Standard dose (1–2 g)	Every 24–48 hours (treat as CrCl <10 — most PD patients have CrCl <10 mL/min)	Not significantly removed by PD. No supplemental dosing needed. ⚠️ Monitor PT/INR.
CRRT (CVVH, CVVHD, CVVHDF)	1–2 g	Every 12–24 hours (dependent on CRRT modality and effluent rate — generally equivalent to CrCl ~20–40 mL/min)	CRRT provides continuous clearance. Dose depends on filter type, flow rates, and sieving coefficient. Cefotetan’s high protein binding limits filtration → less removed than low-protein-bound drugs. Starting recommendation: 1–2 g IV q12–24h. Adjust based on clinical response. ICU pharmacist/nephrologist input recommended.

Formulation-Specific Renal Adjustment

Not applicable — cefotetan is available ONLY as a parenteral injection formulation. No IR vs MR/ER/CR distinction exists. The same vial is used for all dosing modifications (dose and interval adjustment).

Surgical Prophylaxis in Renal Impairment

For patients with CKD undergoing elective surgery: give the standard pre-operative prophylactic dose (1–2 g IV) regardless of renal function — a single prophylactic dose does NOT require renal adjustment. The prolonged half-life in CKD actually extends tissue coverage post-operatively (a pharmacokinetic advantage). ⚠️ However, if post-operative prophylaxis is continued (up to 24 hours — not recommended beyond this), subsequent doses should be adjusted per the renal dosing table above.

Paediatric Renal Adjustment

eGFR (mL/min/1.73 m²)	Dose Adjustment
>30	No adjustment. Standard weight-based dosing (20–40 mg/kg/dose q12h).
10–30	Standard per-dose amount (mg/kg); extend interval to q24h.
<10	Standard per-dose amount; extend interval to q48h.
Haemodialysis	Standard dose q24h. No routine supplemental dose post-HD (minimal dialysability). Paediatric nephrologist involvement mandatory.

ℹ️ Paediatric renal function estimation: Use the bedside Schwartz formula (CKiD equation: eGFR = 0.413 × height [cm] / serum creatinine [mg/dL]).

Augmented Renal Clearance (ARC)

⚠️ Clinically relevant for ICU patients:

ARC (CrCl >130 mL/min) is common in young, non-elderly ICU patients with sepsis, polytrauma, burns, and febrile neutropenia. Cefotetan is 50–80% renally cleared → ARC can cause subtherapeutic levels with standard q12h dosing.

Recommendations for ARC:

Consider shortening the dosing interval to q8h (instead of q12h) — this increases the %fT > MIC but also increases NMTT exposure per 24 hours (increased coagulopathy risk)
If available: therapeutic drug monitoring (TDM) to confirm adequate free drug levels — rarely available for cefotetan
⚠️ If using q8h dosing in ARC: monitor PT/INR more frequently (every 2–3 days) and ensure vitamin K₁ prophylaxis is in place
In practice: ARC patients with serious infections typically require broader-spectrum IV agents (piperacillin-tazobactam, carbapenems) — cefotetan is rarely the appropriate choice in this clinical context

ℹ️ Indian context: ARC awareness is growing in Indian ICUs but remains under-recognised. Measured 8-hour or 24-hour CrCl (from timed urine collection) is more accurate than Cockcroft-Gault or CKD-EPI estimates for detecting ARC.

HEPATIC ADJUSTMENT

✅ NO FORMAL HEPATIC DOSE ADJUSTMENT FOR CEFOTETAN ITSELF

Rationale: Cefotetan is NOT hepatically metabolised. It is excreted unchanged via the kidneys (~50–80%) and bile (~20%). Hepatic impairment does not directly alter cefotetan pharmacokinetics. No formal Child-Pugh-based dosing data exists, and none is needed based on PK principles.

⚠️ HOWEVER: HEPATIC DISEASE DRAMATICALLY AMPLIFIES NMTT-RELATED COAGULOPATHY

This is the critical hepatic consideration for cefotetan — NOT a pharmacokinetic dose adjustment issue, but a pharmacodynamic toxicity amplification issue.

Hepatic Impairment Severity	Dose Adjustment?	NMTT Coagulopathy Risk	Clinical Action
Child-Pugh A (Mild)	✅ No dose adjustment	⚠️ Moderately increased	Baseline PT/INR. Vitamin K₁ 10 mg IV/IM at initiation. Recheck PT/INR at day 3.
Child-Pugh B (Moderate)	✅ No dose adjustment for cefotetan itself	⚠️ Significantly increased — reduced hepatic vitamin K cycling + reduced clotting factor synthesis + possible hypoalbuminaemia (↑ free drug fraction)	⚠️ Baseline PT/INR. Vitamin K₁ 10 mg IV/IM at initiation, then 10 mg every 3 days. PT/INR every 2–3 days. Consider using cefoxitin instead (no NMTT risk — eliminates the hepatic safety concern entirely).
Child-Pugh C (Severe)	✅ No pharmacokinetic dose adjustment needed	⚠️ VERY HIGH — near-absolute risk	⛔ AVOID cefotetan if possible. Use cefoxitin (no NMTT side chain), ampicillin-sulbactam, or amoxicillin-clavulanate instead. If cefotetan is the ONLY option: mandatory vitamin K₁ 10 mg IV at initiation and every 2 days, PT/INR every 1–2 days, FFP available on standby. ⚠️ Patients with decompensated cirrhosis (Child-Pugh C) often have pre-existing coagulopathy (elevated INR from impaired clotting factor synthesis) — NMTT from cefotetan will FURTHER worsen this coagulopathy, potentially to dangerous levels.

Additional Hepatic Considerations

Hypoalbuminaemia in Liver Disease

Patients with cirrhosis/chronic liver disease commonly have hypoalbuminaemia (serum albumin <3.0 g/dL)
Cefotetan’s high protein binding (~76–91%) means that hypoalbuminaemia → increased free drug fraction → higher peak free drug levels + potentially faster clearance
Clinical implication: may see slightly higher free drug concentrations (potentially better bactericidal effect) but also more rapid elimination and amplified NMTT toxicity per dose
No formal dose adjustment for hypoalbuminaemia — but awareness of this PK alteration is important

Active Metabolites

Not applicable — cefotetan has NO active metabolites. However, the NMTT moiety released during drug elimination is a pharmacologically active (toxic) fragment — it does NOT accumulate specifically due to hepatic impairment, but its effects (vitamin K antagonism) are amplified when hepatic vitamin K cycling is already impaired.

Concurrent Hepatotoxin Note

✅ Cefotetan itself has negligible hepatotoxicity risk. It does NOT cause drug-induced liver injury (DILI). Transient mild LFT elevations (~1–3%) may occur — usually clinically insignificant and often attributable to the underlying infection.

Concurrent hepatotoxic drugs — interaction assessment:

Concurrent Drug	Hepatic Interaction from Cefotetan?	NMTT Interaction?	Clinical Note
Rifampicin (anti-TB)	⛔ None hepatic	✅ No CYP interaction (cefotetan not CYP-metabolised)	Safe from hepatic perspective. However, rifampicin can alter gut flora → additive gut vitamin K depletion → increased NMTT coagulopathy risk. Monitor PT/INR.
Isoniazid / Pyrazinamide (anti-TB)	⛔ None hepatic from cefotetan	No CYP interaction	Safe from PK perspective. If patient on ATT develops hepatitis AND needs antibiotics: cefotetan is safe for the liver (not hepatotoxic); monitor PT/INR for NMTT effect.
Methotrexate	⛔ None hepatic	Possible renal OAT competition → ↓ methotrexate clearance (theoretical — see Drug Interactions, Part 4)	For high-dose methotrexate: avoid concurrent cefotetan. For low-dose methotrexate: monitor CBC.
Valproate	⛔ None hepatic from cefotetan	No direct NMTT-valproate interaction	Both valproate and NMTT can independently affect haemostasis (valproate → thrombocytopenia/platelet dysfunction). ⚠️ If co-administered: monitor PT/INR AND platelet count.
Antiretrovirals (NRTIs, NNRTIs, PIs)	⛔ None — cefotetan has zero CYP involvement	No interaction	Safe combination. No hepatic concern from cefotetan.
Paracetamol (acetaminophen)	⛔ None	None	Safe at standard doses.
Amoxicillin-clavulanate (if sequential use — e.g., IV cefotetan → oral amoxicillin-clavulanate step-down)	N/A — sequential, not concurrent	N/A	No hepatic concern from cefotetan. Clavulanate has its own DILI risk (cholestatic — uncommon).
Warfarin / Acenocoumarol	⛔ None hepatic	⚠️ MAJOR interaction — additive coagulopathy (NMTT + warfarin/acenocoumarol both antagonise vitamin K cycling)	See Major Drug Interactions (Part 4).

Formulation-Specific Hepatic Adjustment

Not applicable — cefotetan is available ONLY as a parenteral injection formulation. No IR vs MR/ER/CR distinction exists.

Summary Table: Hepatic Safety of Cefotetan vs Indian-Available Cephamycin (Cefoxitin) in Liver Disease

Parameter	Cefotetan	Cefoxitin
Hepatic metabolism	None	None
Hepatic dose adjustment needed?	No (PK)	No (PK)
NMTT side chain?	⚠️ YES — coagulopathy risk amplified in liver disease	✅ NO — no coagulopathy risk
Disulfiram reaction risk?	⚠️ YES	✅ NO
Hepatotoxicity risk (DILI)?	Negligible	Negligible
Safe in Child-Pugh C?	⚠️ Avoid — high NMTT coagulopathy risk	✅ Yes — no NMTT concern
Vitamin K₁ supplementation needed?	⚠️ YES — mandatory in liver disease	✅ Not required
Available in India?	⛔ No	✅ Yes

💡 Clinical bottom line for Indian prescribers: If a cephamycin antibiotic is needed in a patient with liver disease → use cefoxitin (available in India, no NMTT side chain, no hepatic safety concerns). There is no clinical scenario in Indian practice where cefotetan would be preferred over cefoxitin in a patient with liver disease.

PREGNANCY

Overall Safety Statement

✅ Compatible with use in pregnancy — with NMTT-specific caveats. Cephalosporins and cephamycins as a class have extensive pregnancy safety data with no consistent teratogenic signal. Cefotetan is used in pregnancy-specific contexts (PID in pregnancy per CDC guidelines). However, the NMTT side chain introduces pregnancy-specific safety considerations related to neonatal coagulopathy.

Former US-FDA Pregnancy Category: B (animal studies have not demonstrated fetal risk; clinical experience supports safety). Provided for reference only — India does not use this classification system.

Trimester-Specific Risk Assessment

Trimester	Risk Assessment	Details
First Trimester (Weeks 1–12)	✅ Low risk — Compatible	No consistent evidence of teratogenicity with cephalosporin/cephamycin class. Organogenesis window (weeks 3–8 post-conception) does not appear to be affected.
Second Trimester (Weeks 13–26)	✅ Low risk — Compatible	No specific concerns. Standard doses adequate. Maternal GFR increases → cefotetan clearance accelerated → serum levels may be slightly lower. Standard doses remain adequate.
Third Trimester (Weeks 27–40) / Peripartum	⚠️ Compatible BUT with NMTT caveats	Cefotetan crosses the placenta → fetal/neonatal exposure to both cefotetan AND its NMTT moiety occurs. ⚠️ NMTT-related risk to the neonate: The NMTT side chain can interfere with neonatal vitamin K–dependent clotting factors, potentially contributing to or worsening neonatal coagulopathy — particularly in preterm neonates or neonates who did NOT receive vitamin K prophylaxis at birth (uncommon but occurs in some Indian home deliveries). Risk is primarily theoretical at single-dose exposures (e.g., surgical prophylaxis for C-section) but becomes more relevant with multi-day courses near term.

Teratogenicity Window

No teratogenic risk identified at any stage of pregnancy. Safe throughout all trimesters from a teratogenicity perspective. The concern is not malformation but neonatal coagulopathy with peripartum/third-trimester exposure (see above).

Preferred Alternatives in Indian Obstetric Practice

Situation	Preferred Agent	Role of Cefotetan
C-section prophylaxis	Cefazolin 2 g IV (FOGSI/ACOG first-line; NLEM-listed; no NMTT risk)	Acceptable alternative if anaerobic coverage specifically needed (complicated C-section) — but cefoxitin preferred over cefotetan (no NMTT). In India: cefazolin is first-line.
PID in pregnancy (inpatient)	Cefoxitin 2 g IV q6h + Doxycycline 100 mg oral q12h (CDC Regimen B adapted for India)	Cefotetan is listed in CDC Regimen A but unavailable in India. Use cefoxitin.
Chorioamnionitis	Ampicillin + Gentamicin ± Metronidazole/Clindamycin	Cefotetan is NOT standard for chorioamnionitis.
UTI / Pyelonephritis in pregnancy	Ceftriaxone IV (NLEM) or Cephalexin oral (NLEM) — culture-guided	Cefotetan rarely indicated.

Monitoring During Pregnancy

Mother: Standard adverse effect monitoring. ⚠️ If cefotetan used in third trimester or peripartum: check maternal PT/INR. Administer vitamin K₁ prophylaxis.
Neonate: ⚠️ If the mother received cefotetan within 7 days before delivery: ensure the neonate receives vitamin K₁ 1 mg IM at birth (standard neonatal vitamin K prophylaxis — should be given to ALL neonates in India regardless of antibiotic exposure, but is especially critical here). Monitor neonatal PT/INR if any bleeding signs (cephalhaematoma expansion, umbilical oozing, unexpected bruising).

Pre-Conception Counselling

Not applicable — cefotetan is a short-course antibiotic. No pre-conception washout. No contraception requirement.

Pregnancy Prevention Programme / Registry

Not applicable.

Fertility Effects

No known adverse effect on male or female fertility. No impact on spermatogenesis, ovulation, or ovarian reserve at therapeutic doses. No washout period before planned conception needed.

LACTATION

Overall Compatibility

✅ COMPATIBLE WITH BREASTFEEDING — with awareness of NMTT transfer.

Parameter	Details
Excretion into breast milk	Present in breast milk in low concentrations. Cephalosporins/cephamycins as a class are excreted in small amounts.
Relative Infant Dose (RID)	Data limited for cefotetan specifically. Based on cephalosporin class data: estimated RID is <3% — well below the 10% threshold.
Qualitative milk level	Low
Compatibility statement	✅ Compatible with breastfeeding. No need to discontinue breastfeeding during cefotetan therapy.

⚠️ NMTT-Specific Lactation Consideration

While the absolute amount of cefotetan (and its NMTT moiety) transferred via breast milk is small, the theoretical concern exists that NMTT exposure via milk could contribute to vitamin K–dependent coagulopathy in the breastfed infant — particularly in:

Preterm or very low birth weight infants
Infants who did NOT receive vitamin K₁ at birth
Infants with liver disease or cholestasis (impaired vitamin K cycling)

Clinical action: For the vast majority of healthy, term, breastfed infants who received vitamin K₁ at birth: no specific concern. Continue breastfeeding. Monitor infant for unusual bruising or bleeding (extremely unlikely). If the infant is preterm or at risk: ensure vitamin K₁ prophylaxis has been given and monitor clinically.

What to Monitor in the Breastfed Infant

Loose stools / mild diarrhoea (most common — transient, due to alteration of gut flora)
Oral candidiasis (thrush) — uncommon
Unexplained bruising or bleeding (extremely rare — NMTT-related; relevant only if infant’s vitamin K status is compromised)
Allergic skin rash (very rare)

Timing Advice

Not critical — the amount excreted is very low regardless of timing.

Effect on Milk Production

No known effect on milk production.

Temporary Incompatibility

Not applicable — cefotetan is compatible with breastfeeding. No pump-and-discard period required.

ELDERLY

Definition

≥60 years (consistent with Indian Census and National Programme for Health Care of the Elderly definitions).

Dosing in Elderly

Parameter	Recommendation
Starting dose	⚠️ Dose per RENAL FUNCTION — not age. Calculate CrCl (Cockcroft-Gault) before prescribing. If CrCl >30 mL/min: standard doses (1–2 g IV q12h). If CrCl 10–30: standard dose q24h. If CrCl <10: standard dose q48h.
Titration	Not applicable (antibiotic — fixed dosing).

PK Considerations in Elderly

Cefotetan AUC and Cmax may be significantly higher in elderly patients (35–80% increase vs younger adults) — primarily due to age-related GFR decline. The already-long half-life (~3–4.6 hours) is further prolonged in elderly patients with impaired renal function → increased drug accumulation and NMTT metabolite accumulation.

💡 Critical practical point for Indian elderly patients: Many elderly Indian patients with “normal” serum creatinine (0.8–1.2 mg/dL) have CrCl of only 30–50 mL/min due to low muscle mass (sarcopaenia), vegetarian diet, and small body habitus. Always calculate CrCl. A 75-year-old Indian woman weighing 50 kg with serum creatinine 1.0 mg/dL has a Cockcroft-Gault CrCl of approximately 34 mL/min — borderline for dose adjustment.

Extra Risks Specific to Elderly

Risk	Details	Monitoring / Action
⚠️ NMTT-related coagulopathy	THE most important elderly concern for cefotetan. Elderly patients are at the HIGHEST risk for NMTT-induced coagulopathy due to: (1) age-related decline in vitamin K stores; (2) dietary insufficiency (common in hospitalised elderly Indian patients); (3) polypharmacy with anticoagulants (warfarin/acenocoumarol — very common in elderly Indian patients with AF, prosthetic valves, DVT history); (4) liver function decline; (5) renal impairment → NMTT accumulation; (6) concurrent NPO status in perioperative elderly patients.	⚠️ MANDATORY: Vitamin K₁ 10 mg IV at initiation. PT/INR at baseline and every 2–3 days. Review concurrent anticoagulants. If any coagulopathy develops → stop cefotetan, give vitamin K₁, switch to cefoxitin.
⚠️ Occult renal impairment	GFR declines with age. “Normal” creatinine may mask CrCl <30 mL/min.	MANDATORY: Calculate CrCl before prescribing. Adjust dose per renal table.
⚠️ C. difficile colitis	Elderly are the highest-risk group for CDI. Risk amplified by concurrent PPI, recent hospitalisation, recent antibiotics, nursing home residence.	Monitor for diarrhoea. Use shortest effective course. Review PPI indication — deprescribe if no ongoing need.
Disulfiram reaction risk	Many elderly Indian patients consume alcohol-containing Ayurvedic/Unani tonics, homoeopathic tinctures, or alcohol-based cough syrups regularly. They may not consider these “alcohol.”	⚠️ Specifically ask about ALL medications, tonics, and traditional medicine use. Counsel that ALL alcohol-containing products must be avoided during therapy and for 72 hours after.
Polypharmacy	Cefotetan has a relatively clean CYP450 interaction profile (no CYP involvement). However, the NMTT side chain creates PHARMACODYNAMIC interactions with anticoagulants, antiplatelet agents, and hepatotoxins.	Review medication list specifically for: warfarin/acenocoumarol, aspirin, clopidogrel, NSAIDs (additive bleeding risk), valproate (additive haemostasis effects).
Falls / Delirium	Cefotetan does NOT cause sedation or confusion at standard doses. No direct falls risk. However, elderly patients with NMTT-induced coagulopathy who FALL are at high risk of subdural haematoma / intracranial haemorrhage.	No specific falls precaution from cefotetan itself, but the consequence of a fall is magnified if coagulopathy is present.

Anticholinergic Burden

No anticholinergic burden. Cefotetan has no anticholinergic properties. ACB score = 0.

Beers Criteria / STOPP-START Relevance

Cefotetan is NOT listed in the Beers Criteria or STOPP criteria as a potentially inappropriate medication in the elderly. No age-based prescribing restriction beyond renal adjustment and NMTT precautions.

Deprescribing Guidance

Deprescribing: Not applicable. Cefotetan is a short-course antibiotic. Ensure the prescribed course duration is appropriate and not unnecessarily prolonged (NMTT risk increases with duration).

MAJOR DRUG INTERACTIONS

Interacting Drug / Substance	Mechanism	Clinical Effect	Onset Type	Action Required
⛔ Ethanol (Alcohol) — ALL sources	NMTT side chain inhibits aldehyde dehydrogenase → acetaldehyde accumulation when alcohol consumed	⚠️ Disulfiram-like reaction: flushing, nausea, vomiting, headache, tachycardia, hypotension, diaphoresis, abdominal cramps. Can be severe (cardiovascular collapse).	Acute onset — within 15–30 minutes of alcohol ingestion during or within 72 hours after cefotetan therapy	⛔ ABSOLUTE ALCOHOL AVOIDANCE during therapy and for 72 hours after last dose. Includes: beverages, alcohol-containing medications (⚠️ many Indian cough syrups, tonics, homoeopathic tinctures contain 5–40% ethanol), alcohol-based mouthwashes, alcohol-containing IV medications. Counsel patient AND nursing staff. If reaction occurs: supportive care (IV fluids, monitoring, vasopressors if severe hypotension). 💡 Cefoxitin does NOT cause this — preferred alternative. 💡 Indian context: Cefoperazone-sulbactam (widely used in India) has the SAME NMTT-alcohol interaction — prescribers familiar with the cefoperazone-alcohol warning will recognise the identical mechanism in cefotetan.
⚠️ Warfarin / Acenocoumarol	DUAL mechanism: (1) NMTT side chain → vitamin K antagonism (same target as warfarin — additive); (2) Gut flora disruption → reduced bacterial vitamin K synthesis → further potentiation of anticoagulant effect	⚠️ Significant, potentially dangerous INR elevation → risk of major haemorrhage (GI, intracranial, surgical site, retroperitoneal). This is a PHARMACODYNAMIC interaction — NOT CYP-mediated. Much more severe than the modest gut-flora-mediated INR increase seen with non-NMTT antibiotics.	Gradual onset — INR changes manifest within 2–5 days of starting cefotetan. May be faster in patients with marginal vitamin K stores.	⚠️ Check INR before starting cefotetan. Recheck INR at day 2, day 4, and every 2–3 days during concurrent therapy. Anticipate need for warfarin/acenocoumarol dose REDUCTION (often 25–50% reduction needed). Administer prophylactic Vitamin K₁ 10 mg IV at cefotetan initiation. If INR >4 without bleeding: hold anticoagulant, give vitamin K₁, recheck in 24 hours. If INR >4 WITH bleeding: stop cefotetan AND anticoagulant, give vitamin K₁ 10 mg IV stat + FFP 15 mL/kg. 💡 Strongly consider using cefoxitin instead — eliminates the NMTT component of this interaction entirely (residual interaction is only the modest gut-flora effect common to all antibiotics). ℹ️ India-specific: Acenocoumarol (Acitrom) is more commonly used than warfarin in India — same monitoring and adjustment applies.
⚠️ Heparin (UFH / LMWH)	NMTT-induced hypoprothrombinemia is additive with heparin anticoagulation — different clotting pathways targeted but combined bleeding risk	⚠️ Increased bleeding risk. While the interaction is less dramatic than with warfarin (heparin affects antithrombin pathway, NMTT affects vitamin K pathway), the combined haemostatic impairment can be clinically significant in post-surgical patients.	Acute onset (heparin) + Gradual onset (NMTT effect — 2–5 days)	Monitor aPTT (for UFH), anti-Xa (for LMWH), AND PT/INR (for NMTT effect). Vitamin K₁ prophylaxis. Be aware that PT/INR prolongation in a patient on heparin + cefotetan may be NMTT-related (not heparin-related) — check factor-specific assays if diagnostic confusion arises.
⚠️ Probenecid	Probenecid inhibits renal tubular secretion of cefotetan (OAT1/OAT3 competition) → reduced renal clearance → increased cefotetan AUC (~50–100% increase) and prolonged half-life	Elevated and prolonged cefotetan levels → increased NMTT exposure → amplified coagulopathy and disulfiram-reaction risk. At standard doses, the pharmacokinetic change alone may not cause direct toxicity (wide therapeutic index), but the NMTT amplification is clinically significant.	Immediate — from first concurrent dose	⚠️ If concurrent use unavoidable: reduce cefotetan dose or extend interval. Monitor PT/INR more frequently. Vitamin K₁ prophylaxis. In practice, probenecid is rarely co-prescribed with cefotetan. Probenecid is infrequently used in Indian practice (primarily for gout; replaced by febuxostat).
⚠️ Live oral vaccines (Ty21a oral typhoid, oral cholera vaccine, BCG)	Antibacterial activity can inactivate live bacterial vaccine strains	⚠️ Reduced vaccine efficacy	Acute onset — immediate	⛔ Wait ≥3 days (preferably 7 days) after completing cefotetan before administering oral live bacterial vaccines. Injectable/inactivated vaccines (Vi polysaccharide typhoid, injectable cholera) are NOT affected. Live viral vaccines (MMR, varicella, OPV) NOT affected by antibiotics.
⚠️ Antiplatelet agents (Aspirin, Clopidogrel, Prasugrel, Ticagrelor)	NMTT-induced hypoprothrombinemia + antiplatelet effect = additive bleeding risk from two different haemostatic pathways	⚠️ Increased bleeding risk — particularly at surgical sites in post-operative patients receiving both cefotetan prophylaxis and antiplatelet therapy	Gradual onset (NMTT — 2–5 days; antiplatelet — immediate)	Monitor for clinical bleeding. PT/INR monitoring (NMTT effect on coagulation cascade). Vitamin K₁ prophylaxis. ⚠️ In post-cardiac/vascular surgery patients on dual antiplatelet therapy: avoid cefotetan — use cefazolin (no NMTT, no bleeding amplification). Cefotetan is NOT appropriate for clean cardiac/vascular surgery prophylaxis anyway (no anaerobic coverage needed).

Major Food-Drug Interactions

Food / Substance	Mechanism	Clinical Effect	Action
⛔ Alcohol — ALL forms (see interaction table above)	NMTT → aldehyde dehydrogenase inhibition	Disulfiram-like reaction	Absolute avoidance — see detailed guidance above
⚠️ Alcohol-containing traditional medicines (Ayurvedic asava/arishta preparations, homoeopathic mother tinctures, Unani formulations)	Same mechanism	Same reaction	⚠️ India-specific — critical: Many patients do not consider traditional medicines as “alcohol-containing.” Prescribers must specifically ask about Ayurvedic asava/arishta (e.g., Ashwagandharishta, Draksharishta, Dashmularishta — these contain 5–12% self-generated alcohol), homoeopathic tinctures (ethanol-based), and Unani preparations. Counsel to discontinue ALL such preparations during therapy and for 72 hours after.

Herb-Drug / Traditional Medicine Interactions (Major)

Substance	Mechanism	Clinical Effect	Action
⚠️ Ayurvedic asava/arishta preparations	Alcohol content (5–12% v/v) → disulfiram-like reaction with NMTT-containing antibiotics	Flushing, nausea, vomiting, hypotension	⛔ Discontinue during cefotetan therapy and for 72 hours after. Traditional medicine interaction.

MODERATE DRUG INTERACTIONS

Interacting Drug / Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Aminoglycosides (gentamicin, amikacin, tobramycin) — in-vitro incompatibility	Physical/chemical incompatibility when mixed in same IV solution — beta-lactam ring inactivates aminoglycoside amino groups → loss of activity of BOTH drugs. ℹ️ In vivo, the combination may provide additive bactericidal activity (therapeutic benefit) when administered correctly via separate lines.	(1) If mixed in same line/bag: inactivation of both drugs → therapeutic failure. (2) If administered separately: potential therapeutic benefit (additive killing).	Incompatibility: immediate on contact. Therapeutic synergy: immediate.	⛔ NEVER mix in same IV bag, syringe, or line. Administer through separate IV lines or flush with ≥20 mL NS between drugs (≥30-minute separation). Monitor aminoglycoside levels if concurrent use in renal impairment.
Oral contraceptive pills (COCPs)	Theoretical gut flora disruption → reduced enterohepatic recirculation of ethinylestradiol. Current evidence does NOT strongly support reduced COCP efficacy with non-enzyme-inducing antibiotics.	ℹ️ No clinically significant interaction — theoretical only.	N/A	ℹ️ No additional contraceptive precautions needed. Exception: if severe diarrhoea/vomiting impairs COCP absorption → barrier contraception until 7 days after GI symptoms resolve.
NSAIDs (ibuprofen, diclofenac, naproxen)	NMTT-induced hypoprothrombinemia + NSAID antiplatelet/GI ulcerogenic effects = additive bleeding risk	⚠️ Increased GI and non-GI bleeding risk	Gradual onset (NMTT — 2–5 days; NSAID — immediate)	Monitor for clinical bleeding. If NSAIDs needed for pain: use paracetamol as first-line analgesic (no antiplatelet effect). If NSAIDs unavoidable: add PPI gastroprotection, monitor PT/INR, vitamin K₁ prophylaxis.
Methotrexate (low-dose — RA/psoriasis)	Possible reduced renal tubular secretion of methotrexate (OAT transporter competition — class effect of beta-lactams)	Theoretical increased methotrexate levels → toxicity (mucositis, pancytopaenia, nephrotoxicity). Clinical significance at low methotrexate doses (7.5–25 mg/week) is uncertain but awareness is appropriate.	Acute onset (renal competition)	Monitor CBC at day 7 of concurrent use. For high-dose methotrexate (oncologic): interaction is classified as MAJOR — avoid concurrent use (see Major Drug Interactions table).
Iron supplements (ferrous sulphate, ferrous fumarate)	No significant interaction documented for cefotetan	No interaction	N/A	✅ No separation of doses needed.
PPIs (omeprazole, pantoprazole)	No pharmacokinetic interaction (cefotetan is parenteral; PPI effect on gastric pH irrelevant). Concurrent PPI use increases CDI risk (additive with antibiotic CDI risk).	ℹ️ No PK interaction. Additive CDI risk is pharmacodynamic.	N/A (CDI risk — gradual)	Review PPI indication — deprescribe if no ongoing need, especially in elderly patients on cefotetan.
Valproate	No direct CYP or PK interaction. Both valproate and NMTT independently affect haemostasis: valproate → thrombocytopenia/platelet dysfunction; NMTT → hypoprothrombinemia.	⚠️ Additive haemostatic impairment from two different mechanisms — clinically relevant in patients on both drugs.	Gradual onset	Monitor PT/INR AND platelet count. Vitamin K₁ supplementation.
Cyclosporine / Tacrolimus	No CYP3A4 interaction (cefotetan has zero CYP involvement). No P-gp interaction.	ℹ️ No clinically significant interaction. Safe for transplant patients.	N/A	✅ No dose adjustment of immunosuppressant needed.

COMMON ADVERSE EFFECTS

ℹ️ Cefotetan’s adverse effect profile is broadly similar to other cephalosporins/cephamycins, EXCEPT for the NMTT-specific effects (hypoprothrombinemia, disulfiram-like reaction with alcohol) which are unique to NMTT-containing beta-lactams and are discussed as Serious Adverse Effects below.

Very Common (≥10%)

ℹ️ None — no single adverse effect occurs at ≥10% incidence with cefotetan at standard doses in clinical trials. Overall tolerability is good.

Common (1–10%)

Adverse Effect	System	Incidence	Details
Diarrhoea	GI	~3–8%	Most common ADR. Usually mild, non-bloody, self-limiting. Due to disruption of normal gut flora. More common with prolonged courses (>7 days). If severe, watery, bloody, or febrile → rule out C. difficile infection.
Nausea	GI	~2–5%	Usually mild and transient.
Phlebitis / Thrombophlebitis at IV site	Local	~3–8%	Moderate risk. Dilute adequately (≥50 mL for infusion), infuse over ≥20 minutes, rotate IV sites every 48–72 hours. For courses >5 days: consider midline/PICC.
Pain at IM injection site	Local	~5–10% (of IM doses)	IM cefotetan is moderately painful. Reconstitute with 0.5–1% lidocaine to reduce pain.
Rash (maculopapular, non-urticarial, delayed)	Dermatological	~2–4%	Non-IgE-mediated, delayed (onset >72 hours). Self-limiting after stopping drug. Document as “cefotetan-associated non-allergic rash” — NOT as “cephalosporin allergy” unless accompanied by systemic features (urticaria, angioedema, haemodynamic changes).
Urticaria (true allergic)	Dermatological / Immunological	~1–2%	IgE-mediated if immediate (<1 hour). Stop cefotetan. Document as genuine beta-lactam allergy. Manage with antihistamines ± corticosteroids. If progressive → treat as anaphylaxis.
Transient eosinophilia	Haematological	~2–5%	Mild drug hypersensitivity phenomenon. Usually incidental laboratory finding. If isolated eosinophilia with stable renal function: monitor, no action. If eosinophilia + rising creatinine → suspect AIN (very rare).
Transient LFT elevation	Hepatic	~2–4% (AST/ALT/ALP)	Mild, clinically insignificant. NOT true hepatotoxicity (cefotetan has zero hepatic metabolism). Usually infection-related or coincidental. No action needed.
Positive direct Coombs test (DAT)	Haematological / Laboratory	~3–5% (may be higher with prolonged courses)	ℹ️ Positive DAT is common with cephalosporins/cephamycins (class effect — drug coats RBC surface → anti-drug antibody binds). Clinical haemolysis is RARE. However, a positive DAT complicates crossmatching for blood transfusion. Alert blood bank if patient is on cefotetan. See Laboratory Test Interference.

Dose-Response Threshold

Diarrhoea and GI effects: Modestly dose-dependent — more common at 2 g q12h than 1 g q12h and with courses >7 days.
Phlebitis: More common with concentrated solutions (>40 mg/mL) and rapid infusion.
NMTT-related effects (hypoprothrombinemia): Clearly dose- and duration-dependent — onset typically after 3–5 days, more severe with higher total daily doses and prolonged courses. See Serious Adverse Effects.

SERIOUS ADVERSE EFFECTS

⚠️ Report ALL serious adverse effects to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on CDSCO website (www.cdsco.gov.in). PvPI Helpline: 1800-180-3024 (toll-free).

⚠️ SIGNATURE ADR: NMTT-Induced Hypoprothrombinemia / Coagulopathy

⚠️ Cefotetan-Specific (Signature ADR) — This adverse effect is UNIQUE to NMTT side chain–containing beta-lactams (cefotetan, cefamandole, cefoperazone, moxalactam) and does NOT occur with non-NMTT cephalosporins/cephamycins (cefoxitin, cefuroxime, cefazolin, ceftriaxone, etc.).

Parameter	Details
Incidence	Clinically significant coagulopathy: ~2–5% of patients receiving cefotetan for >5 days (higher in at-risk populations — see risk factors below). Subclinical PT prolongation (laboratory only, no bleeding): ~10–20% of patients on multi-day courses.
Timing	Onset typically 3–5 days after starting therapy. May occur earlier (day 2) in patients with severe vitamin K deficiency or liver disease. Continues for 1–3 days after stopping cefotetan (NMTT has its own elimination half-life).
Mechanism	The NMTT (N-methylthiotetrazole) moiety, released during cefotetan metabolism/elimination, inhibits vitamin K epoxide reductase and vitamin K–dependent gamma-carboxylase in the liver — the same enzymes targeted by warfarin. This impairs synthesis of functional clotting factors II (prothrombin), VII, IX, and X. The effect is mechanistically identical to warfarin but generally less potent at therapeutic cefotetan doses — unless risk factors amplify the effect.
Risk factors for clinically significant coagulopathy	(1) Prolonged courses (>5–7 days) — highest risk factor; (2) Malnutrition / vitamin K deficiency — very common in hospitalised Indian patients; (3) Pre-existing liver disease (impaired vitamin K cycling); (4) Concurrent anticoagulant therapy (warfarin/acenocoumarol — additive vitamin K antagonism); (5) Renal impairment (drug/NMTT accumulation); (6) NPO status (no dietary vitamin K intake); (7) Bowel sterilisation by the antibiotic itself (reduced gut bacterial vitamin K synthesis); (8) Concurrent bile duct obstruction (impaired bile salt–dependent vitamin K absorption); (9) Neonates and infants (low vitamin K stores); (10) Elderly (all of the above risk factors converge)
Clinical manifestation	Prolonged PT/INR → ecchymosis (bruising), oozing from IV/surgical sites, wound haematoma, epistaxis, gum bleeding, haematuria, melena/haematochezia, retroperitoneal haemorrhage (rare, severe), intracranial haemorrhage (rare, usually in setting of concurrent anticoagulant or fall).

Detailed Management Protocol

Severity	PT/INR	Bleeding?	Management
Subclinical	PT prolonged (INR 1.5–2.5) but NO clinical bleeding	No	Administer Vitamin K₁ 10 mg IV (slow push over 10 min or diluted in 50 mL NS over 15–20 min). Recheck PT/INR at 6–12 hours. Continue cefotetan only if clinical benefit outweighs coagulopathy risk — otherwise switch to cefoxitin (no NMTT).
Mild bleeding	INR 2.5–4.0	Minor (bruising, oozing, epistaxis controlled with local measures)	Stop cefotetan. Vitamin K₁ 10 mg IV stat. Recheck INR at 6 hours. If INR not improving → repeat vitamin K₁. Local haemostasis measures. Switch to cefoxitin or other non-NMTT alternative. ⚠️ Report to PvPI.
Moderate bleeding	INR >4.0	Moderate (haematuria, melena, wound haematoma requiring intervention)	Stop cefotetan immediately. Vitamin K₁ 10 mg IV stat. Fresh Frozen Plasma (FFP) 15 mL/kg for immediate clotting factor replacement. Repeat INR at 4–6 hours. Crossmatch blood (note: DAT may be positive — alert blood bank). Surgical haemostasis if wound haematoma expanding. Switch antibiotic. ⚠️ Report to PvPI.
Severe / Life-threatening bleeding	INR >6.0 or any level with major haemorrhage	Severe (GI haemorrhage, retroperitoneal bleed, intracranial haemorrhage)	Stop cefotetan immediately. Vitamin K₁ 10 mg IV stat. FFP 15–20 mL/kg URGENT. Consider 4-Factor Prothrombin Complex Concentrate (4F-PCC) 25–50 IU/kg IV if available (faster reversal than FFP — available at some Indian tertiary centres). Transfuse packed RBC for significant blood loss. ICU admission. Neurosurgical/surgical consultation as appropriate. Repeat vitamin K₁ q12h × 3 doses (NMTT effect persists after drug stopped). ⚠️ Report to PvPI.

Re-Challenge / Recurrence Policy

⚠️ Do NOT re-challenge with cefotetan after clinically significant NMTT-induced coagulopathy. Switch to cefoxitin (same spectrum, no NMTT) or other appropriate alternative.
The NMTT-related coagulopathy is a predictable, dose/duration-dependent pharmacological effect — NOT an idiosyncratic/allergic reaction. Re-exposure will reproduce the effect. Unlike true drug allergy, this is a toxicity that can be prevented (vitamin K₁ prophylaxis) or managed — but re-challenge without compelling reason is not justified when alternatives exist.

Cross-Reactivity Implications

⚠️ The NMTT-related coagulopathy will also occur with OTHER NMTT-containing beta-lactams: cefamandole, cefoperazone (available in India), and moxalactam/latamoxef. Avoid ALL NMTT-containing drugs after cefotetan-induced coagulopathy.
✅ Safe alternatives: Cefoxitin, cefazolin, cefuroxime, ceftriaxone, cefepime, ampicillin-sulbactam, amoxicillin-clavulanate, piperacillin-tazobactam, carbapenems — NONE of these contain the NMTT side chain.

Other Serious Adverse Effects

Adverse Effect	Approximate Frequency	Details	Action Required
⛔ Anaphylaxis	Rare (~1–5 per 100,000 courses)	IgE-mediated Type I hypersensitivity. Onset: within 5–30 minutes of IV/IM dose. Features: urticaria, angioedema, bronchospasm, laryngeal oedema, hypotension, cardiovascular collapse.	⛔ STOP immediately. Adrenaline (Epinephrine) 0.5 mg IM (1:1000, 0.5 mL) into anterolateral thigh — repeat q5 min. Adjuncts: oxygen, IV NS bolus, salbutamol nebulisation, IV hydrocortisone 200 mg, IV chlorpheniramine 10 mg. Lifetime ban on cefotetan. Formal allergy assessment before future beta-lactam. Adrenaline available at ALL levels of Indian healthcare. ⚠️ Report to PvPI.
⚠️ Disulfiram-like reaction (with alcohol)	Dependent on alcohol exposure — 100% risk if NMTT-containing drug + alcohol; 0% if alcohol completely avoided	NMTT-mediated inhibition of aldehyde dehydrogenase. Features: flushing, nausea, vomiting, headache, tachycardia, hypotension, diaphoresis. Severity: mild discomfort to cardiovascular collapse. Onset: within 15–30 minutes of alcohol ingestion.	STOP alcohol exposure. Supportive care: IV fluids, monitoring, vasopressors if severe hypotension. Antiemetics for vomiting. Most cases resolve within 2–4 hours with supportive care. ⚠️ Report to PvPI.
⚠️ Clostridioides difficile-associated diarrhoea (CDAD)	~0.5–2%	During therapy or up to 8 weeks after. Features: profuse watery/bloody diarrhoea, cramps, fever. Severe: toxic megacolon, perforation.	STOP cefotetan. Test C. difficile toxin. Treat: Oral vancomycin 125 mg QDS × 10 days (first-line) or Fidaxomicin 200 mg BD × 10 days. Metronidazole 400–500 mg TDS × 10 days if vancomycin unavailable. ⛔ No antimotility agents. ⚠️ Report to PvPI.
⚠️ Immune haemolytic anaemia (Coombs-positive)	Rare (<0.1% — but positive DAT without haemolysis occurs in 3–5%)	Drug-induced immune haemolytic anaemia. Positive direct Coombs test (DAT). Clinical haemolysis manifests as: falling Hb, reticulocytosis, elevated LDH/indirect bilirubin, low haptoglobin, spherocytes on smear. More common with prolonged, high-dose therapy. ℹ️ Cefotetan has been reported to cause haemolytic anaemia at a potentially higher rate than some other cephalosporins — though data is limited and confounded by concomitant conditions.	STOP cefotetan if clinically significant haemolysis. DAT, reticulocyte count, haptoglobin, LDH, bilirubin. Haematology referral if severe. Transfusion may be complicated by positive DAT (crossmatch difficulty — alert blood bank). Most cases resolve after drug withdrawal. ⚠️ Report to PvPI.
⚠️ Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)	Very rare (<1 per 100,000)	Severe mucocutaneous reaction. Onset: 7–21 days. Prodromal fever → painful macules → blistering → epidermal detachment. Mucosal involvement. Mortality: SJS ~5%, TEN ~25–30%.	⛔ STOP immediately. Urgent dermatology + burns unit/ICU referral. Supportive care. Ophthalmology consult. ⛔ Avoid ALL cephalosporins/cephamycins lifelong without formal allergy evaluation. ⚠️ Report to PvPI.
⚠️ DRESS Syndrome	Very rare	Onset: 2–8 weeks. Fever + rash + eosinophilia + organ involvement. Mortality ~5–10%.	⛔ STOP immediately. Systemic corticosteroids. Monitor organ functions. ⚠️ Report to PvPI.
⚠️ Serum sickness-like reaction	Uncommon	Onset: 7–21 days. Fever, arthralgia, urticarial rash, lymphadenopathy.	STOP drug. Antihistamines, NSAIDs (with caution — bleeding risk with NMTT), short-course corticosteroids. Self-limiting 1–3 weeks. ⚠️ Report to PvPI.
⚠️ Acute Interstitial Nephritis (AIN)	Very rare	Fever, rash, eosinophilia, rising creatinine, eosinophiluria.	STOP drug. Nephrology referral. Consider corticosteroids. ⚠️ Report to PvPI.
⚠️ Seizures / Neurotoxicity	Exceedingly rare at standard doses	Beta-lactam neurotoxicity — primarily in severe renal impairment with drug accumulation.	Adjust dose per renal function. Benzodiazepines for seizure management. ⚠️ Report to PvPI.

Antidote / Reversal Information

Toxicity	Antidote / Reversal	Dose	Availability in India
NMTT-induced coagulopathy	Vitamin K₁ (Phytomenadione) — FIRST-LINE	10 mg IV (adults) slow push over 10 min or diluted in 50 mL NS over 15–20 min. Children: 1–5 mg IV/IM. Repeat q12h × 3 doses if needed.	✅ Widely available — NLEM-listed. Available at PHC level.
NMTT-induced coagulopathy (acute severe bleeding)	Fresh Frozen Plasma (FFP) — for immediate clotting factor replacement	15–20 mL/kg IV	✅ Available at blood banks in district hospitals and above
NMTT-induced coagulopathy (life-threatening — faster reversal)	4-Factor Prothrombin Complex Concentrate (4F-PCC)	25–50 IU/kg IV	⚠️ Limited availability — select tertiary centres only (e.g., AIIMS, CMC Vellore, TMC Mumbai, major corporate hospitals). NOT available at most district hospitals.
Anaphylaxis	Adrenaline (Epinephrine)	Adults: 0.5 mg IM (1:1000); Children: 0.01 mg/kg IM (max 0.3 mg) — repeat q5 min	✅ Available at ALL levels including PHCs
Disulfiram-like reaction	No specific antidote — supportive care	IV fluids, monitoring, vasopressors if severe hypotension	Supportive care available at all hospital levels
CDI	Oral Vancomycin (first-line)	125 mg QDS × 10 days	✅ Available at district hospitals and above
Seizures	Lorazepam or Midazolam	Lorazepam 2–4 mg IV; Midazolam 0.1–0.2 mg/kg IV/IM	✅ Available at district hospitals and above

CDSCO Safety Alerts / Black Box Warnings

No India-specific CDSCO alert exists for cefotetan (drug is not marketed in India). In the US, the FDA-approved labelling carries warnings for:

Disulfiram-like reaction with alcohol (NMTT)
Hypoprothrombinemia (NMTT) — with recommendation for vitamin K prophylaxis in at-risk patients
CDI risk
Haemolytic anaemia (Coombs-positive)

LABORATORY TEST INTERFERENCE

Test	Type of Interference	Clinical Implication	Alternative Test Method
Direct Coombs Test (DAT / Direct Antiglobulin Test)	False-positive — drug coats RBC surface → anti-drug antibody binds → positive DAT without true autoimmune haemolysis. Incidence: ~3–5% with cefotetan (cephalosporin class effect).	⚠️ Complicates blood crossmatching — may delay transfusion. May be misdiagnosed as autoimmune haemolytic anaemia. In most cases, DAT is positive WITHOUT clinical haemolysis (haemoglobin stable, no reticulocytosis).	Alert blood bank before ordering crossmatch. If DAT is positive: check reticulocyte count, haptoglobin, LDH, indirect bilirubin to distinguish drug-induced DAT positivity (no haemolysis) from true haemolytic anaemia (haemolysis markers elevated).
Urine Glucose — Copper-Reduction Methods (Benedict’s reagent, Clinitest)	False-positive glucose readings	May lead to unnecessary insulin administration or diabetic workup in non-diabetic patients. Still relevant in Indian PHC/CHC settings where older methods may be used.	✅ Use enzymatic glucose oxidase methods (glucometer strips — NOT affected by cephalosporins).
Serum Creatinine — Jaffé Reaction	Possible minor interference (positive bias — falsely elevated creatinine). Cephalosporin class effect, though clinically insignificant at cefotetan’s therapeutic serum concentrations.	May marginally overestimate serum creatinine → underestimate eGFR. Unlikely to be clinically significant in practice.	Enzymatic creatinine assays are unaffected. If Jaffé method is the only available assay (common in Indian district hospital labs): be aware of potential minor overestimation.
PT / INR	True prolongation (NOT a false-positive — this is a REAL pharmacological effect of the NMTT side chain)	⚠️ PT/INR prolongation in a patient on cefotetan represents actual hypoprothrombinemia caused by NMTT-mediated vitamin K antagonism. This is NOT a laboratory artefact — it reflects genuine coagulation impairment. Do NOT dismiss prolonged PT/INR in a patient on cefotetan as “lab error.”	No alternative method needed — the prolonged PT/INR is real and clinically significant. Manage as per the NMTT coagulopathy protocol (Signature ADR section above).
Urinary 17-Ketosteroids	False elevation reported (rare, historical — relevant mainly for older endocrine assays)	May confuse endocrine workup if the assay is used.	Modern immunoassay-based hormone measurements are NOT affected.

MONITORING REQUIREMENTS

⚠️ NMTT-SPECIFIC MONITORING — THE MOST CRITICAL MONITORING CONSIDERATION FOR CEFOTETAN

The monitoring requirements for cefotetan are substantially more extensive than for non-NMTT cephalosporins/cephamycins (cefoxitin, cefuroxime, cefazolin, ceftriaxone) because of the NMTT side chain–related coagulopathy and disulfiram-reaction risks. If the prescriber finds these monitoring requirements burdensome → this is itself a reason to choose cefoxitin (no NMTT, no coagulation monitoring needed) over cefotetan when a cephamycin is required.

Baseline (Before Starting)

Parameter	Priority	Details	Resource-Limited Setting Surrogate
Allergy history — beta-lactam	MANDATORY	Detailed history of previous penicillin, cephalosporin, or cephamycin reactions. Classify as mild/moderate/severe using the Penicillin Allergy Decision Table (Part 4). Ask specifically about: nature of reaction (rash vs urticaria vs anaphylaxis), timing (minutes vs days), severity, rechallenge history.	Same — clinical history. No substitute.
PT / INR	MANDATORY (for cefotetan specifically — NOT required for cefoxitin, cefuroxime, cefazolin)	⚠️ Baseline PT/INR is MANDATORY before starting cefotetan — to establish pre-treatment coagulation status. If PT is already prolonged at baseline (liver disease, warfarin therapy, malnutrition, vitamin K deficiency): the risk of NMTT-induced coagulopathy is significantly amplified. Consider choosing cefoxitin instead. If baseline INR >1.5 without therapeutic anticoagulation: investigate cause AND administer vitamin K₁ before starting cefotetan.	If PT/INR testing unavailable (resource-limited setting): ⚠️ Do NOT use cefotetan — use cefoxitin (no NMTT, no coagulation monitoring needed). If cefotetan is the ONLY available option: clinical assessment for bleeding signs (bruising, petechiae, gum bleeding), check for liver disease stigmata, review medications for anticoagulants. Give empirical vitamin K₁ 10 mg IM prophylactically.
Serum creatinine + eGFR/CrCl calculation	MANDATORY	Cefotetan is 50–80% renally eliminated. Dose interval adjustment required when CrCl ≤30 mL/min. Renal impairment also causes NMTT metabolite accumulation → amplified coagulopathy risk. Use Cockcroft-Gault for CrCl. ⚠️ In elderly Indian patients: always calculate — “normal” serum creatinine frequently masks significant CrCl reduction.	If serum creatinine unavailable: assess urine output (>0.5 mL/kg/hr), oedema, known CKD history, concurrent nephrotoxic drugs. Use conservative dosing (q24h) if renal function uncertain and patient is elderly.
Infection-specific cultures	MANDATORY (for UTI — urine C&S; for IAI — peritoneal fluid culture at surgery; for sepsis — blood cultures ×2) / RECOMMENDED (for SSTI — wound culture; for PID — STI screening) / OPTIONAL (for surgical prophylaxis)	Obtain BEFORE first dose whenever possible. ⚠️ India-specific: ESBL prevalence is 20–70% — culture confirmation of susceptibility is essential for gram-negative infections.	If culture unavailable: Gram stain if microscopy available. Start empirical therapy. Refer for formal C&S if no response at 48–72 hours.
Complete blood count (CBC)	RECOMMENDED	Baseline WBC (infection severity), haemoglobin (baseline before potential NMTT-related bleeding), platelet count (if concurrent valproate or antiplatelet therapy).	Clinical assessment of pallor, petechiae, signs of severe infection.
Liver function tests (LFTs)	RECOMMENDED (to identify liver disease that amplifies NMTT coagulopathy risk — NOT because cefotetan is hepatotoxic)	Baseline AST, ALT, ALP, bilirubin, albumin, total protein. If liver disease is identified: ⚠️ NMTT coagulopathy risk is amplified → use cefoxitin instead if available, or give more aggressive vitamin K₁ prophylaxis with closer PT/INR monitoring.	If LFTs unavailable: clinical assessment for liver disease stigmata (jaundice, spider naevi, ascites, hepatomegaly, palmar erythema). If liver disease suspected clinically: use cefoxitin (no NMTT risk).
Alcohol use history	MANDATORY (for cefotetan specifically)	⚠️ Ask about: (1) Current alcohol consumption (frequency, type, quantity); (2) Alcohol-containing medications — ⚠️ specifically ask about Ayurvedic asava/arishta preparations (Ashwagandharishta, Draksharishta, Dashmularishta — 5–12% alcohol), homoeopathic mother tinctures, Unani preparations, alcohol-based cough syrups/tonics; (3) Plans for alcohol consumption during hospitalisation or within 72 hours post-discharge. If the patient is unable or unwilling to abstain from alcohol for 72 hours after therapy → do NOT use cefotetan. Use cefoxitin.	Same — clinical history.
Nutritional status assessment	RECOMMENDED	Malnourished patients (⚠️ extremely common in Indian hospitalised patients — particularly elderly, post-operative, and patients with chronic illness) have low vitamin K stores → amplified NMTT coagulopathy. BMI, serum albumin, and clinical nutritional assessment guide vitamin K₁ prophylaxis intensity.	Clinical assessment: cachexia, temporal wasting, BMI <18.5, history of poor dietary intake. If malnutrition suspected: empirical vitamin K₁ 10 mg IV/IM at cefotetan initiation.

For specific indications — additional mandatory baseline:

Indication	Additional Baseline
PID	⚠️ MANDATORY: Pregnancy test (rule out ectopic pregnancy), STI screening (GC/CT NAAT), pelvic ultrasound, HIV and syphilis screening.
Surgical prophylaxis	Allergy history confirmation. No additional labs beyond standard pre-operative workup.
IAI	Peritoneal fluid cultures at surgery. CT abdomen if abscess suspected.

After Initiation / Dose Change

Parameter	Timing	Details
PT / INR	⚠️ Day 3 (first recheck), then day 5, then every 3–5 days during therapy	THE most important follow-up parameter for cefotetan. NMTT-induced hypoprothrombinemia typically manifests at day 3–5. If PT prolonged (INR >1.5 unexplained or rising trend): administer vitamin K₁ 10 mg IV. If clinically significant (INR >2.5 or any bleeding): stop cefotetan, switch to cefoxitin, manage coagulopathy per Signature ADR protocol (Part 4). ℹ️ This monitoring is NOT required for cefoxitin, cefuroxime, cefazolin, or ceftriaxone.
Clinical response assessment	48–72 hours	Fever curve, symptom improvement, inflammatory markers (WBC, CRP). If no improvement → reassess: culture results, imaging for undrained collection, alternative diagnosis (TB in India), resistant organism, need to broaden coverage.
Bleeding assessment (clinical)	Daily — by nursing staff	Check for: bruising, oozing from IV/surgical sites, gum bleeding, epistaxis, haematuria, melena. Any new bleeding → immediate PT/INR check → manage per Signature ADR protocol.
Repeat cultures	48–72 hours (for bloodstream infections only)	Repeat blood cultures to document clearance. Not routine for IAI, SSTI, or UTI if clinical response adequate.
Serum creatinine	Day 3–5 (for patients on concurrent nephrotoxic drugs or with baseline renal impairment)	Recheck to detect renal function deterioration → if CrCl declines below 30 mL/min: adjust cefotetan interval. Renal impairment also amplifies NMTT accumulation.
INR in anticoagulated patients	Day 1–2, then every 2 days during concurrent cefotetan + warfarin/acenocoumarol	Anticipate need for anticoagulant dose reduction. See Major Drug Interactions (Part 4).

Long-Term / Maintenance Monitoring

ℹ️ Cefotetan courses are typically short (single dose for surgical prophylaxis; 4–14 days for treatment). Long-term monitoring (>14 days) is rarely needed but applicable for complex bone/joint infections or complicated IAI.

Parameter	Frequency	Details
PT / INR	Every 3–5 days for entire duration of therapy	NMTT coagulopathy risk increases with duration. If course exceeds 7 days → vitamin K₁ 10 mg IV/IM weekly is MANDATORY.
CBC	Weekly if course >7 days	Monitor for neutropenia, thrombocytopenia, anaemia (haemolytic — DAT-related, or blood loss from NMTT coagulopathy).
Serum creatinine	Weekly during prolonged courses	Detect renal function changes → adjust dose interval.
LFTs	OPTIONAL — only if clinical concern	Cefotetan has negligible hepatotoxicity. LFT rise usually infection-related.
DAT (Direct Coombs test)	Only if haemolysis suspected (falling Hb with reticulocytosis)	Not routine. If DAT positive with stable Hb and no haemolysis markers: no action needed (common false-positive with cephalosporins). If DAT positive WITH haemolysis markers: stop cefotetan, haematology referral.
Stool monitoring	Ongoing — clinical assessment	New-onset diarrhoea → test for C. difficile toxin. CDI can occur up to 8 weeks after stopping.

Therapeutic Drug Monitoring (TDM)

ℹ️ Not routinely performed. No established therapeutic range. TDM for cefotetan is not available at most Indian (or international) laboratories. The primary PK/PD target (%fT > MIC) is achieved with standard dosing in patients with normal renal function. If available (research settings): free drug trough level >4× MIC of the target pathogen is a reasonable goal.

When to Stop Monitoring

For single-dose surgical prophylaxis: PT/INR recheck is NOT routinely needed (single dose rarely causes significant coagulopathy in patients without risk factors). If risk factors present (anticoagulated, liver disease, malnutrition): check PT/INR on post-operative day 1.
For short courses (≤5 days): PT/INR at day 3 is the minimum. If normal and no risk factors: no further coagulation monitoring needed.
For courses >5 days: Continue PT/INR monitoring every 3–5 days until course completion + 72 hours after last dose (NMTT effect persists).

ℹ️ Common Investigation Misconception Flag

ℹ️ PT/INR prolongation in a patient on cefotetan is NOT a “laboratory artefact” or “drug interference” — it represents REAL hypoprothrombinemia caused by NMTT-mediated vitamin K antagonism. Do NOT dismiss it. It requires clinical action (vitamin K₁ administration, dose/drug reassessment). This is a commonly misunderstood finding when clinicians unfamiliar with the NMTT mechanism assume the PT prolongation is spurious.

Resource-Limited Setting Surrogates — Summary Table

Monitoring Parameter	Clinical Surrogate When Test Unavailable
PT / INR	⚠️ If PT/INR is unavailable: DO NOT use cefotetan. Use cefoxitin instead (no NMTT → no coagulation monitoring needed). If cefotetan is the ONLY option: clinical bleeding assessment (daily check for new bruising, oozing, gum/nasal bleeding, haematuria, melena) by nursing staff. Give prophylactic vitamin K₁ 10 mg IM to ALL patients.
Serum creatinine / CrCl	Urine output monitoring. History of kidney disease, oedema. Conservative dosing (q24h) if renal function unknown and patient is elderly.
CBC	Pallor (anaemia), petechiae/bleeding (thrombocytopenia), worsening infection (neutropenia).
LFTs	Clinical liver disease stigmata (jaundice, ascites, spider naevi). If present: use cefoxitin.
Alcohol use	Direct patient/family questioning — no laboratory substitute.
Nutritional status	BMI estimation, clinical assessment (cachexia, temporal wasting). If malnourished: vitamin K₁ prophylaxis mandatory.

PATIENT COUNSELLING

(Written in simple language for the prescribing doctor to convey to the patient during consultation)

ℹ️ Context note: Cefotetan is a hospital-administered IV/IM antibiotic — not a self-administered outpatient medication. Patient counselling below is oriented toward inpatient education (what the patient/family should know while receiving the drug in hospital and during the post-discharge period).

What This Medicine Is For

“This is a strong antibiotic given through the vein (drip) or as an injection to treat your infection. It kills the bacteria (germs) causing your infection — including certain germs that live in places without oxygen in the body (like the belly and pelvic area).”

How It Is Given

“This medicine is given by the nurse through your drip (IV line) over 20–60 minutes, or as an injection into the muscle. You do NOT take this medicine by mouth.”
“You will usually receive this medicine twice a day (every 12 hours — for example, 8 AM and 8 PM).”
“If you are receiving this medicine before surgery (to prevent infection): you will get one dose before the operation. You do NOT usually need it after the surgery.”

⚠️ The Most Important Warning — NO ALCOHOL

⚠️ “You must NOT drink ANY alcohol while receiving this medicine — and for AT LEAST 3 FULL DAYS (72 hours) after your last dose.”

“If you drink alcohol (even a small amount), this medicine will react with the alcohol in your body and cause a very unpleasant and potentially dangerous reaction: severe nausea, vomiting, flushing (face turning red and hot), fast heartbeat, headache, dizziness, and in severe cases, your blood pressure can drop dangerously low.”
"This includes ALL types of alcohol:
- Beer, wine, spirits (whisky, rum, vodka, brandy, toddy, arrack)
- ⚠️ Ayurvedic asava/arishta medicines (like Ashwagandharishta, Draksharishta, Dashmularishta) — these contain alcohol even though they are ‘herbal’
- ⚠️ Homoeopathic tinctures (mother tinctures) — these are alcohol-based
- ⚠️ Cough syrups and tonics — many contain alcohol. Ask your pharmacist or doctor before taking any cough syrup, tonic, or supplement
- Alcohol-based mouthwash (if you swallow any)
- Alcohol-based hand sanitisers applied to large areas of broken skin (unlikely to cause reaction from intact skin)"
“This rule applies even AFTER you leave the hospital — avoid all alcohol and alcohol-containing products for 3 full days after your last dose of this medicine.”

Warning About Bleeding Risk

⚠️ “This medicine can sometimes affect your blood’s ability to clot properly. Tell your nurse or doctor immediately if you notice:”

“Unusual bruising (blue/black marks on your skin that you did not expect)”
“Oozing or bleeding from your drip site, surgical wound, or any cut”
“Bleeding from your gums when brushing teeth”
“Blood in your urine (red or dark brown urine)”
“Black or bloody stools”
“Nosebleeds that do not stop easily”
“Any unusual bleeding anywhere”

“Your doctor may give you a vitamin (Vitamin K) injection to help prevent this problem.”

Common Side Effects to Expect

“You may get loose stools or mild diarrhoea — this is common. Tell your nurse if the diarrhoea is severe, bloody, watery, or comes with stomach cramps and fever.”
“The area around your drip may become slightly sore or red — tell the nurse so they can change the drip site.”
“If you get the medicine as a muscle injection, it may be painful at the injection site — this is normal and usually gets better within a day.”

Warning Signs — Tell Your Nurse/Doctor Immediately

⚠️ “Difficulty breathing, swelling of face/lips/tongue/throat — this is an emergency”
⚠️ “Severe skin rash with blisters, peeling, or sores in your mouth/eyes”
⚠️ “Severe diarrhoea (bloody, watery, many times a day) with fever — can happen even weeks after you stop this medicine”
⚠️ “Any unexplained bleeding or bruising (see list above)”
⚠️ “Yellow colour of eyes or skin”

Things to Avoid

⛔ ALL alcohol and alcohol-containing products — during treatment AND for 72 hours after last dose (see detailed list above)
“Tell your doctor about ALL medicines you are taking — especially blood-thinning medicines (warfarin / Acitrom)”
“Tell your doctor about ALL Ayurvedic, homoeopathic, or herbal medicines you are taking”

Duration

“This medicine is for a specific course to treat your infection. The length of the course depends on the type of infection.”
“Your doctor will decide when to stop this medicine and may switch you to a different antibiotic taken by mouth.”

Follow-Up

“Your doctor will order blood tests (to check your blood clotting and kidney function) during your treatment.”
“After leaving the hospital, come back if: diarrhoea develops (even weeks later), unusual bleeding or bruising occurs, or your symptoms return.”

Common Patient Questions

“Can I take this during fasting (Ramadan/Navratri)?”

“This medicine is given through the drip (IV) — it does not go through your stomach. Receiving IV medicines does NOT break most religious fasts. However, please discuss with your religious advisor if you have concerns. ⚠️ The important thing is that you must NOT consume any alcohol-containing traditional medicines, tonics, or beverages during your fast or at any time while on this medicine.”

“Will this affect my ability to drive/work?”

“This medicine does not cause drowsiness or affect your ability to think clearly. However, you are in hospital receiving IV treatment — you should not be driving or working while hospitalised.”

“Can I take this if I am pregnant or breastfeeding?”

“Tell your doctor if you are pregnant or breastfeeding. This medicine can be used during pregnancy if needed, but your doctor will take special precautions (a vitamin K injection may be needed). It is compatible with breastfeeding.”

Caregiver / Family Counselling

“Counsel the caregiver/family member on:”

✔ ⛔ No alcohol — ensure the family does NOT bring alcohol-containing beverages, tonics, Ayurvedic asava/arishta, homoeopathic tinctures, or alcohol-containing cough syrups to the patient during hospitalisation or for 3 days after discharge
✔ Bleeding watch — alert nursing staff immediately if they notice new bruising, bleeding from drip/wound site, blood in urine/stool, or nosebleed
✔ Post-discharge diarrhoea — if severe/bloody diarrhoea develops even weeks after discharge, bring the patient back to hospital (CDI risk)
✔ Complete the course — if the patient is switched to oral antibiotics at discharge, ensure the full prescribed course is completed
✔ Vitamin K₁ — if the patient is discharged on oral antibiotics after receiving cefotetan IV, remind the family that any remaining bleeding risk from cefotetan will resolve within 72 hours. No ongoing vitamin K supplementation is usually needed after discharge unless specifically prescribed.

India-Specific Adherence Support

💡 Not applicable in the usual sense — cefotetan is a hospital-administered IV drug, not an outpatient self-administered medication. Adherence is managed by nursing staff. The relevant “adherence” issue is ensuring the patient and family understand the post-discharge alcohol avoidance period (72 hours) and the warning signs of bleeding/CDI that should prompt return to hospital.

💡 Cost-driven non-adherence: Not applicable for cefotetan (not available in India). If the patient is switched to oral step-down antibiotics at discharge (e.g., amoxicillin-clavulanate): counsel about completing the full oral course. “If cost is a concern, ask your doctor about generic amoxicillin-clavulanate from Jan Aushadhi stores.”

BRANDS AVAILABLE IN INDIA

⛔ NO BRANDS AVAILABLE IN INDIA

Cefotetan is NOT marketed in India. No CDSCO-approved formulation from any Indian or international manufacturer is identified as commercially available in Indian pharmacies, hospitals, or government supply chains.

❌ No Jan Aushadhi / PMBJP brand
❌ No private Indian brands
❌ No government supply
❌ No NLEM listing

Historical / International Brand (For Reference Only)

Brand Name	Manufacturer	Formulations	Market	Current Status
Cefotan®	AstraZeneca / Zeneca (US)	1 g, 2 g powder for injection; 1 g/50 mL, 2 g/50 mL premixed frozen	United States	⚠️ Supply has been intermittent in recent years even in the US market. Production by original manufacturer may be discontinued; generic versions from US generic manufacturers (Sandoz, Sagent) have also had supply issues.

Indian Alternative — Cefoxitin Brands

For Indian prescribers needing a cephamycin antibiotic (the same pharmacological subclass as cefotetan), cefoxitin is available:

Brand Name	Manufacturer	Strengths	Availability
Mefoxin (generic equivalents)	Multiple Indian manufacturers	1 g, 2 g powder for injection	Widely available
Cefomycin	Aristo Pharmaceuticals	1 g injection	Widely available
Foxim	Lupin Pharmaceuticals	1 g, 2 g injection	Metro/urban availability
Cefoxitin (generic)	Hetero, Gland Pharma, others	1 g, 2 g injection	Widely available

PRICE RANGE (INR)

Cefotetan

Not applicable — drug is NOT marketed in India. No Indian pricing data exists.

ℹ️ International reference pricing (US market, for context only — NOT actionable for Indian practice): In the US, cefotetan injection has historically been priced at approximately US$30–80 per 1 g vial and US$50–120 per 2 g vial (wholesale acquisition cost). These prices are NOT relevant to Indian prescribers.

Comparative Cost Context — Indian-Available Alternatives

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

Drug	Typical Per-Vial/Per-Day Cost (INR)	Per-Course Cost (7-Day Typical)	NLEM Status	Availability
Cefotetan (1 g / 2 g vial)	⛔ Not available in India	N/A	❌ Not listed	⛔ Not available
Cefoxitin (1 g vial)	₹80–200 per vial; ~₹320–800/day (1 g q6h)	₹2,240–5,600 per 7-day course	❌ Not NLEM-listed	✅ Widely available
Cefoxitin (2 g vial)	₹150–350 per vial; ~₹600–1,400/day (2 g q6h)	₹4,200–9,800 per 7-day course	❌ Not NLEM-listed	✅ Widely available
Cefuroxime injection (750 mg vial)	₹60–180 per vial; ~₹180–540/day (750 mg q8h)	₹1,260–3,780 per 7-day course	✅ NLEM-listed (750 mg, 1.5 g)	✅ Widely available
Cefuroxime injection (1.5 g vial)	₹120–350 per vial; ~₹360–1,050/day (1.5 g q8h)	₹2,520–7,350 per 7-day course	✅ NLEM-listed	✅ Widely available
Metronidazole injection (500 mg/100 mL)	₹15–40 per bottle; ~₹45–120/day (500 mg q8h)	₹315–840 per 7-day course	✅ NLEM-listed	✅ Widely available
Cefuroxime + Metronidazole (combination)	~₹225–660/day + ~₹45–120/day = ₹270–780/day	₹1,890–5,460 per 7-day course	✅ Both NLEM-listed	✅ Both widely available
Amoxicillin-clavulanate injection (1.2 g vial)	₹80–200 per vial; ~₹240–600/day (1.2 g q8h)	₹1,680–4,200 per 7-day course	✅ NLEM-listed	✅ Widely available
Ampicillin-sulbactam injection (1.5 g vial)	₹40–120 per vial; ~₹160–480/day (1.5 g q6h)	₹1,120–3,360 per 7-day course	❌ Not NLEM-listed (ampicillin is NLEM-listed)	✅ Widely available
Cefazolin injection (1 g vial) — for clean surgical prophylaxis	₹15–60 per vial; single dose ₹15–60	Single dose (prophylaxis)	✅ NLEM-listed	✅ Widely available

💡 Key cost-effectiveness insight: The most cost-effective Indian alternative providing combined aerobic + anaerobic coverage (the reason cefotetan is chosen in international guidelines) is the Cefuroxime + Metronidazole combination — both drugs are NLEM-listed, NPPA price-controlled, widely available, and when combined provide the same spectrum coverage as cefotetan. Total daily cost: ₹270–780 — significantly less than cefoxitin monotherapy (₹320–1,400/day) and dramatically less than cefotetan (which is unavailable and would be expensive if imported).

CLINICAL PEARLS

💡 1. When international guidelines say “cefotetan” — Indian prescribers should read “cefoxitin” as the direct cephamycin substitute. [Evidence-based]

US-origin guidelines (CDC PID treatment, ASHP surgical prophylaxis, IDSA IAI guidelines) frequently recommend “cefotetan or cefoxitin” interchangeably as cephamycin options. Since cefotetan is unavailable in India and cefoxitin IS available, Indian prescribers should automatically substitute cefoxitin whenever they encounter “cefotetan” in international guidelines. The spectrum is essentially identical (cefoxitin may have slightly better B. fragilis activity). The key differences are: (a) cefoxitin requires q6–8h dosing (vs cefotetan q12h) and (b) cefoxitin has NO NMTT side chain (no disulfiram reaction, no coagulopathy — a SAFETY ADVANTAGE).

💡 2. If you know the cefoperazone-alcohol warning, you already understand the cefotetan-alcohol warning — it’s the SAME mechanism (NMTT side chain). [Evidence-based]

Indian prescribers are much more likely to encounter the NMTT side chain through cefoperazone-sulbactam (widely prescribed in Indian hospitals) than through cefotetan. The NMTT pharmacology is identical: aldehyde dehydrogenase inhibition → disulfiram-like reaction with alcohol. Any prescriber who counsels patients to avoid alcohol with cefoperazone-sulbactam should apply the exact same counselling for cefotetan (if ever encountered). Conversely, if you are prescribing cefoperazone-sulbactam: be aware that it has the SAME coagulopathy risk as cefotetan — monitor PT/INR and give vitamin K₁ prophylaxis for courses >5 days.

💡 3. The cheapest and most widely available “cefotetan equivalent” regimen in India is: Cefuroxime IV + Metronidazole IV — both NLEM-listed, both NPPA price-controlled. [Practice-based]

For infections where combined aerobic + anaerobic coverage is needed (the reason cefotetan is chosen), the combination of cefuroxime 1.5 g IV q8h + metronidazole 500 mg IV q8h provides: (a) excellent aerobic gram-positive and gram-negative coverage (from cefuroxime); (b) excellent anaerobic coverage including B. fragilis (from metronidazole — more reliable than cephamycins given rising cephamycin resistance among anaerobes); © both drugs are NLEM-listed and NPPA-controlled → affordable; (d) cefuroxime allows IV-to-oral step-down within the same molecule (cefuroxime axetil); (e) metronidazole has excellent oral bioavailability (~100%) → seamless oral step-down; (f) neither drug has an NMTT side chain → no disulfiram reaction, no coagulopathy → no PT/INR monitoring needed. The only disadvantage: two separate IV infusions instead of one (but this is offset by the safety and cost advantages).

💡 4. Myth vs Fact: “Cephamycins (cefotetan/cefoxitin) are effective against ESBL-producing organisms because they resist ESBL hydrolysis.”

💡 Myth: Cefotetan and cefoxitin are resistant to ESBL enzymes in vitro, therefore they can be used for ESBL infections.

Fact: While the 7α-methoxy group of cephamycins does confer structural resistance to hydrolysis by ESBLs in laboratory testing, clinical outcomes with cephamycins against ESBL-producing organisms are unreliable. Multiple clinical studies have shown treatment failure rates that are unacceptably high. This is because: (a) ESBL-producing organisms frequently co-harbour other resistance mechanisms (porin loss, AmpC); (b) the inoculum effect — at high bacterial inocula (as in clinical infections), cephamycin MICs rise; © in-vitro susceptibility does not predict clinical success for ESBL infections. ⛔ Do NOT use cefotetan or cefoxitin for documented ESBL infections. Use carbapenems or piperacillin-tazobactam (for non-severe infections) based on susceptibility. This is especially important in India where ESBL prevalence is 20–70%. [Evidence-based — ICMR AMR surveillance data; multiple clinical outcome studies]

💡 5. Cefotetan’s q12h dosing is its only practical advantage over cefoxitin — but this comes at the cost of NMTT-related toxicity that cefoxitin avoids entirely. [Evidence-based]

The pharmacokinetic elegance of cefotetan (long t½ → q12h → single pre-operative dose for long surgeries → less nursing workload) is undeniable. But this advantage is accompanied by two clinically significant liabilities that cefoxitin entirely avoids: (a) disulfiram-like reaction with alcohol; (b) hypoprothrombinemia/coagulopathy requiring vitamin K₁ prophylaxis and PT/INR monitoring. In Indian clinical practice — where patients are frequently malnourished (low vitamin K), may consume alcohol-containing traditional remedies unknowingly, and where coagulation monitoring may not be readily available outside tertiary centres — the safety profile of cefoxitin is distinctly superior. The practical conclusion: the dosing convenience of cefotetan does NOT justify its use over cefoxitin in any setting where cefoxitin is available.

💡 6. For surgical prophylaxis requiring anaerobic coverage in India: the simplest and safest single-agent option is cefoxitin 2 g IV pre-op. The simplest and cheapest two-drug option is cefazolin 2 g IV + metronidazole 500 mg IV pre-op. [Practice-based]

When an Indian surgeon reads an international guideline recommending “cefotetan” for colorectal or gynaecological surgical prophylaxis:

Single-agent substitute: Cefoxitin 2 g IV within 60 min of incision (re-dose q2–3h intra-op for long cases) — provides combined aerobic + anaerobic coverage in one drug, no NMTT risk, no special monitoring.
Two-agent substitute: Cefazolin 2 g IV + Metronidazole 500 mg IV within 60 min of incision — cefazolin provides better MSSA coverage than cefoxitin (advantageous for wound infection prevention), metronidazole provides reliable anaerobic coverage (no cephamycin resistance issue), both are NLEM-listed, both are cheap. Cefazolin’s longer half-life (re-dose q4h) is more convenient than cefoxitin’s (re-dose q2–3h).
Either option is pharmacologically appropriate, safe, and available in India.

VERSION

RxIndia v0.1 — 19 Mar 2026

REFERENCES

Listed below are the sources actually used or referenced in generating this monograph:

Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023) — Brunton LL, Knollmann BC (editors). Chapter: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics. Pharmacology of cephamycins (cefotetan, cefoxitin), mechanism of action, PK/PD of beta-lactams, NMTT side chain pharmacology (disulfiram-like reaction mechanism, hypoprothrombinemia mechanism), spectrum of activity, cephalosporin/cephamycin classification, comparative pharmacokinetics (half-life, protein binding, renal elimination), allergy cross-reactivity between beta-lactam subclasses.
Harrison’s Principles of Internal Medicine, 21st Edition (2022) — Jameson JL, Fauci AS, Kasper DL, et al. (editors). Chapters: Treatment of Bacterial Infections, Pelvic Inflammatory Disease, Intra-Abdominal Infections, Surgical Site Infection Prevention, Antimicrobial Resistance.
National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Referenced to confirm cefotetan is NOT NLEM-listed. Referenced for NLEM-listed alternatives: cefazolin injection (1 g), cefuroxime injection (750 mg, 1.5 g), metronidazole injection (500 mg/100 mL), amoxicillin-clavulanate (tablet 500/125 mg; injection 1000/200 mg), ampicillin injection, ceftriaxone injection, vitamin K₁ injection.
National Formulary of India, 6th Edition (2021) — Indian Pharmacopoeia Commission. Cephalosporin class monograph. General dosing, adverse effects, pharmacokinetics. Referenced for cefoxitin monograph data (the Indian-available cephamycin).
ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2019 — Indian Council of Medical Research. Guidance on empirical antibiotic selection, antimicrobial stewardship, ESBL prevalence data in India (used for resistance context throughout this monograph). Referenced for recommendation against cephamycin use for ESBL infections.
API Textbook of Medicine, 11th Edition — Association of Physicians of India. Chapters on: Intra-Abdominal Infections/Peritonitis, Pelvic Inflammatory Disease, Surgical Site Infections, Antimicrobial Stewardship, Anaerobic Infections.
CDC STI Treatment Guidelines, 2021 — Centers for Disease Control and Prevention (US). Referenced for: PID treatment Regimen A (cefotetan-based) and Regimen B (cefoxitin-based), with Indian adaptation notes (using cefoxitin as the available cephamycin in India). CDC guidelines are widely used by Indian O&G specialists for PID management.
Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Am J Health-Syst Pharm 2013; 70:195–283 (ASHP/IDSA/SIS Surgical Prophylaxis Guidelines). Referenced for: surgical prophylaxis recommendations for colorectal, gynaecological, and clean-contaminated procedures. Cefotetan is specifically listed as an option for these procedures in these guidelines.
Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133–164 (SIS/IDSA IAI Guidelines). Referenced for: IAI treatment recommendations and role of cephamycins in community-acquired IAI.
FOGSI (Federation of Obstetric and Gynaecological Societies of India) Guidelines — Referenced for: C-section prophylaxis recommendations (cefazolin as first-line), PID management in Indian obstetric practice.
IAP (Indian Academy of Pediatrics) Guidelines — Referenced for: neonatal sepsis regimen (ampicillin + gentamicin — standard per NNF/IAP/WHO), paediatric intra-abdominal infections, paediatric antibiotic selection.
NNF (National Neonatology Forum of India) Clinical Practice Guidelines — Neonatal Sepsis: Diagnosis and Management. Referenced for: standard neonatal sepsis regimen and recommendation against cefotetan use in neonates.
AIIMS Treatment Guidelines / Protocols — All India Institute of Medical Sciences, New Delhi. Referenced for: surgical prophylaxis protocols, antimicrobial stewardship framework, empirical antibiotic selection for IAI and PID.
NCDC (National Centre for Disease Control) Infection Control Guidelines — Referenced for: surgical prophylaxis recommendations adapted for Indian hospital settings.
NPPA (National Pharmaceutical Pricing Authority) — Drug Price Control Order (DPCO) — Referenced to confirm cefotetan is NOT under NPPA price control (not marketed in India). Referenced for NPPA-controlled pricing of alternatives (cefuroxime, metronidazole, amoxicillin-clavulanate, cefazolin).
PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue. Referenced to confirm cefotetan is NOT available through Jan Aushadhi stores.
CDSCO Approved Drug List and Banned Drug List — Referenced to confirm cefotetan is NOT currently CDSCO-approved/marketed in India and has NOT been banned (never marketed).
PvPI (Pharmacovigilance Programme of India) — ADR reporting guidelines and mechanism. Central Drugs Standard Control Organisation. Available at cdsco.gov.in. Helpline: 1800-180-3024.
NACO (National AIDS Control Organisation) / ICMR National Treatment Guidelines for Gonorrhoea — Referenced for recommendation that cefotetan/cefoxitin should NOT be used for gonorrhoea (gonococcal resistance) — ceftriaxone is current first-line.
Indian Pharmacopoeia 2022 — Indian Pharmacopoeia Commission. Referenced for: cefoxitin sodium monograph (the Indian-available cephamycin).

2nd Gen (Cephamycins — anaerobic cover)

Medication Registry

Cefoxitin

Cefotetan

Explore More

Quick Links